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Summary 
The complement cascade is being increasingly implicated in development and disease.  
To understand these various roles, mouse models have been used and are proving to 
be an excellent tool.  While they have helped to elucidate many roles of central 
cascade components, they do not adequately model complement regulators.  
Complement Receptors 1 (CR1) and 2 (CR2) have been implicated in modifying 
disease states, such as Alzheimer’s disease and Systemic Lupus Erythematosus, but 
they are not well replicated in mice.  This leaves a gap in knowledge about how these 
receptors are functioning.  To overcome this, a mouse model was engineered to 
replace endogenous murine Cr2 with the human complement receptors, CR1 and CR2. 
This model will be an asset to the complement research community, but there is need 
for characterizing the expression of CR1.  This project aims to establish and validate 
this model.  CR1 has an array of allotypes in human populations, and using traditional 
recombination methods (FLP-FRT and Cre recombination) two of the most common 
alleles are replicated within this mouse, along with creating a CR1 knockout allele.  To 
validate the model a variety of techniques were used to ensure the correct targeting of 
the genomic construct into the murine Cr2 locus.  Once integration was confirmed, the 
allelic series was established.  Expression patterns in blood-derived cells were probed 
at an RNA level, with the different isoforms of CR1 being identified at a protein level. 
These models accurately produce viable protein products. These findings ensure that 
an accurate mouse model will be available to the complement research community. 
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1. Introduction  
The innate immune system is the first line of defense for a variety of insults, whether 
this is an infection or at the site of injury.  It is capable of driving regeneration, 
remodelling and restoration in a variety of different tissues, along with protecting our 
systems as a whole from pathogen-mediated damage.  The complement cascade is 
one of the oldest components of the innate immune system and therefore, an integral 
player in the body’s defensive and developmental systems (Wyssokowitsch 1866; 
Nuttall 1888; Ehrlich and Morgenroth 1889; Ehrlich and Morgenroth 1899; Buchner 
1889a; Buchner 1889b; Buchner 1899; Buchner 1900; Bordet 1898; Bordet 1896). 
Central components of the cascade are highly conserved throughout differing species, 
highlighting its evolutionary importance, with bacteria evolving to produce complement 
combating components to defend themselves against attack (van den Berg et al. 
1996). 
Complement has been shown to have a major influence in diseases such as 
glaucoma(Williams et al. 2016; Howell et al. 2013; Howell et al. 2011), Alzheimer’s 
disease (AD)(Shen and Meri 2003; Jun et al. 2010; Mahmoudi et al. 2015; Crehan et 
al. 2012; Fonseca et al. 2016; Lambert et al. 2009; Killick, T. R. Hughes, et al. 2013; 
Fonseca et al. 2011; Strohmeyer et al. 2000; Tooyama et al. 2001; Corneveaux et al. 
2010; Kolev et al. 2009; Brouwers et al. 2012; Van Cauwenberghe et al. 2013; 
Schjeide et al. 2011; Hazrati et al. 2012; Shen et al. 2001; Killick, T.R. Hughes, et al. 
2013; Ma et al. 2014; Carrasquillo et al. 2010; Zhou et al. 2008; Hamilton et al. 2012; 
MM et al. 2010; Biffi 2012; Maier et al. 2008b; Chibnik et al. 2011; Keenan et al. 2012; 
Britschgi et al. 2012; Maier et al. 2008a), Schizophrenia (Arakelyan et al. 2011; Sekar 
et al. 2016), Systemic Lupus Erythematosus (SLE) (Iida et al. 1982; Dykman et al. 
1984; Ross et al. 1985; Richardson et al. 1990; Corvetta et al. 1991; Levy et al. 1992; 
Bowness et al. 1994; Marquart et al. 1995; Moulds et al. 1996; Korb and Ahearn 1997; 
Wu et al. 2002; Arora et al. 2004; Nath et al. 2005; Asokan et al. 2006; Wu et al. 2007), 
and Rheumatoid arthritis (Wilson et al. 1986; Corvetta et al. 1991; Kumar et al. 1994; 
Jones et al. 1994; Arora et al. 1998; Okroj et al. 2007) among many others. While the 
complement cascade components can influence disease progression, some of the 
major factors influencing their efficiency in diseased environments are the complement 
regulators and receptors. These include Complement Receptor 1 (CR1), Complement 
Receptor 2 (CR2), Decay Accelerating Factor (DAF), and Membrane Cofactor Protein 
(MCP), that all have important roles in regulating the responses of the complement 
cascade (reviewed in Merle et al. 2015a; Merle et al. 2015b).  
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1.1 The Complement Cascades 
The complement cascade has three known branches of activation: The Classical 
pathway (Ferrata 1907; Brand 1907), the Alternative pathway (Pillemer et al. 1954; 
Pillemer 1955) and the Lectin pathway (Kawasaki et al. 1978; Kozutsumi et al. 1980) 
(Fig 1). Each pathway is initiated via different triggers; the Classical pathway is 
traditionally thought to be initiated via antibodies (though recent studies suggest that 
they may not be the only instigating factor (Naito et al. 2012; Nayak et al. 2010; Korb 
and Ahearn 1997; Bergamaschini et al. 1999)), the Alternative pathway generally 
initiates via the hydrolysis of a single complement protein and finally the Lectin 
pathway is initiated by the binding of polysaccharides commonly seen on the surface of 
bacteria. Although each pathway is initiated in different ways, all three pathways 
converge to form a convertase that allows for the initiation of the terminal pathway 
(reviewed in Merle et al. 2015a).  While this is the traditionally held view, studies are 
emerging to suggest that there are additional roles for the complement cascade 
proteins, along with a variety of elements that are able to interact at multiple different 
places within the cascade (Amara et al. 2008; Naito et al. 2012; Bergamaschini et al. 
1999). 
With these inherent capabilities and the role of complement cascade components ever 
expanding, from development to disease, there is an urgency to fully understand all of 
its capabilities. Much of the cascade is being delved into and dissected via the use of 
animal models. For instance, of relevance to these studies, the use of these animal 
models has helped to uncover C1q as an integral component of synaptic modelling in 
development (Stevens et al. 2007; Schafer et al. 2012), the impact of C1q and C3 on 
the development and progression of glaucoma (Howell et al. 2011; Williams et al. 
2016), the involvement of a variety of complement components in tissue regeneration 
and growth (Rutkowski et al. 2010; Mastellos and Lambris 2002; Del Rio-Tsonis et al. 
1998), and that regulation of C3 is essential to embryo survival (Xu et al. 2000; Mao et 
al. 2003). Along with this, models have shown that complement can play a hugely 
influential role in the progression of AD (Hazrati et al. 2012; Keenan et al. 2012; Maier 
et al. 2008a; Zhou et al. 2008). Although these breakthroughs have aided in furthering 
our understanding of the complement cascade, these models are limited in their 
genetic ability to mimic human systems accurately.  
1.1.1 Classical Pathway:  
The activation of the Classical pathway is initiated via the binding of antigens to 
complement component 1 (C1) (reviewed in Gál et al. 2004; Sarma and Ward 2011; 
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Merle et al. 2015a).  C1 is made up of a subset of units; C1q, C1r and C1s (C1q6r2s2). 
Once antigen binding occurs structural changes in C1q, permit the activation of C1r 
and C1s. Activated C1s in the C1 complex causes the cleavage of 2 proteins, C4 and 
C2. These proteins are broken down into ‘a’ and ‘b’ fragments (C2a, C2b, C4a and 
C4b). C2b and C4a are released into the fluid phase and are rapidly degraded. C2a 
and C4b are able to bind to the antigen-presenting cell, whether this be self or foreign, 
to form the C4b2a complex which is considered a C3 convertase. This C3 convertase 
can now contribute to the continuation of the cascade. C3 is converted into its 
anaphylatoxin, C3a, and opsonin, C3b. The C3 convertase, C4b2a, is now able to 
interact with C3b and this interaction in turn is considered to be a C5 convertase.  
While the C5 convertase is being formed, C3a is signaling an immune response, and 
attracting a variety of immune cells to the area of activation. 
1.1.2 Lectin Pathway:  
The Lectin pathway instigates a similar chain reaction to the Classical Pathway but is 
initiated via the binding of Mannose Binding Lectin (MBL) or Ficolins to polysaccharide 
residues on the surface of pathogens (reviewed in Gál et al. 2004; Sarma and Ward 
2011; Merle et al. 2015a). Once bound, MBL associated serine proteases (MASP) 
MASP-1 and MASP-2 are activated.  Once activated both MASP-1 and MASP-2 
undergo conformational changes and have the capability to cleave C2 and C4 into their 
respective ‘a’ and ‘b’ fragments (Sarma and Ward 2011).  These then form the C3 
convertase, C4b2a.  Along with the ability to cleave C2 and C4, MASP-1 is also 
capable of cleaving C3 independently (Dahl et al. 2016; Rossi et al. 2001; Thiel et al. 
1997). 
1.1.3 Alternative pathway:  
The Alternative pathway is, at a low level, always active in healthy individuals and 
constantly surveying for pathogens (reviewed in Sarma and Ward 2011; Merle et al. 
2015a). This pathway is activated via the spontaneous hydrolysis of C3, causing a 
cleavage of a thioester bond to form C3(H2O). This event enables a conformational 
change of C3, allowing the binding of Factor B. Upon binding the serine protease, 
Factor D, is able to cleave Factor B into the non-catalytic Ba and catalytic Bb. Bb 
remains integrated with C3(H2O) to form a C3(H2O)Bb complex. This complex is now 
considered a fluid phase C3 convertase and is able to instigate the cleavage of C3 into 
C3b and C3a. The C3(H2O)Bb complex is relatively unstable, but binding of the serum 
protein properdin stabilizes the complex and continues to cleave additional C3.  An 
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additional C3b will then bind to the C3(H2O)Bb complex creating C3(H2O)BbC3b, a C5 
convertase.  
1.1.4 The Terminal pathway:  
Once each pathway has converged upon their individual C5 convertase, the terminal 
pathway can be initiated (Tedesco et al. 2004; Sarma and Ward 2011; Merle et al. 
2015a). The presence of these convertases initiates the conversion of C5 into C5a and 
C5b. C5a is an anaphylatoxin while C5b is recruited to form the membrane attack 
complex (MAC). This complex is established with C5b, C6, C7, C8 and C9 coming 
together into a ring like structure. This structure is able to embed into the membrane of 
the targeted cell, creating a pore and enabling cell lysis. 
 
1.2 Complement components within the cascade: 
Along with their roles of being initiators and integral members of the complement 
cascade itself, recent studies have suggested complement-independent roles of 
cascade components.  These roles are considered to be ‘complement-independent’ as 
they do not follow the traditionally assumed cascades. The three main contenders in 
the complement cascade are C1, C3 and C5.  Each play an integral role within the 
various pathways, but both can be activated via alternative means.  
 6 
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Figure 1. The Three Complement Cascades The complement cascade is comprised 
of multiple factors, traditionally defined by three major pathways. The classical pathway 
is generally activated by antibodies, and cleaves C4 and C2 to make a C3 convertase.  
This convertase is able to cleave C3, releasing an anaphylatoxin (C3a) and an opsonin 
(C3b). C3b interacts with the C3 convertase to form a C5 convertase. This convertase 
is then able to cleave C5 into C5a, an anaphylatoxin, and C5b, which recruits C6-C9 to 
form the membrane attack complex (MAC). The MAC creates a lytic pore in the 
membrane of a target cell, eventually leading to cell death. The Lectin pathway follows 
the same cascade as the classical, but is activated by the binding of MBL to cell 
surface polysaccharides, found on invading pathogens.  The activation of the MBL 
causes conformational changes within MASP-1 and MASP-2, leading to the cleavage 
of C4 and C2, instigating the remainder of the pathway. The alternative pathway is 
activated by spontaneous hydrolisis of C3, which enables the binding of Factor B.  
Factor D is then able to cleave Factor B into its two fragments, Bb and Ba.  Bb remains 
bound to C3(H2O) and this is considered a C3 convertase.  This C3 convertase is then 
able to cleave C3 into C3a and C3b.  C3b is able to bind to this complex creating a C5 
convertase and continuing to the terminal pathway, forming the MAC (as previously 
described). 
Reviewed in: Gál et al. 2004; Tedesco et al. 2004; Sarma and Ward 2011; Merle et al. 
2015a 
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1.2.1 C1 
The C1 complex is the initiating factor of the classical pathway and plays a pivotal role 
in the recognition of immune complexes. It is composed of six C1q molecules, two C1r 
molecules and two C1s molecules. The C1q molecule itself is built from 18 polypeptide 
chains (6A, 6B, 6C) (Kishore and Reid 2000). The C1r and C1s molecules interact to 
form a Ca2+ dependent complex (C1r2-C1s2) that in turn binds to the collagen domains 
of C1q. Once activated, via binding of IgG or IgM, conformational changes occur within 
the collagen region of C1q, this in turn activates C1r, which then activates C1s.  This, 
now active, C1 complex is able to cleave C4 and C2, via C1s, into their fluid phase 
(C2b and C4a) and surface-bound (C2a and C4b) fragments, to form the C3 
convertase. Ultimately, the C1 inhibitor (C1INH) binds to the C1 complex and 
dissociates the C1r2-C1s2 component, leaving the C1q molecule able to interact with 
cell surface receptors while remaining bound to an immune complex.  
Although C1 is traditionally assumed to be activated by antibodies, in more recent 
years C1q has been show to also be activated through a variety of different ligands.  
These include the binding of soluble oligomers such as amyloid beta (Aβ) 
(Bergamaschini et al. 1999) and prion protein (Blanquet-Grossard et al. 2005); direct 
binding to apoptotic cells (Korb and Ahearn 1997); and cardiolipin (Rossen et al. 1994).  
Along with this, C1q has been demonstrated to activate canonical Wnt signaling (Naito 
et al. 2012) thus promoting age related phenotypes, as well as being implicated in the 
polarization of macrophages (Benoit et al. 2012). 
1.2.2 C3  
C3 is the most abundant complement protein (Rodriguez et al. 2015) and is an integral 
component of all three complement cascade pathways. Upon cascade activation, via 
C3 convertases or through spontaneous hydrolysis, C3 is cleaved into an 
anaphylatoxin (C3a) and an opsonin (C3b).  C3a is released into the fluid phase 
surrounding the cell/target and mediates a potent inflammatory response, while C3b 
binds to glycoproteins across the surface of the targeted object. C3b in a C5 
convertase will also bind C5, enabling C2a in the convertase to cleave C5.  The 
production of C3b also creates a positive feedback loop, amplifying its own production 
through auto-activation. In the presence of properdin, the C3 convertase is stabilized 
and protected from cleavage by Factor I (Fearon and Austen 1975; Medicus et al. 
1976; Kemper et al. 2010). C3b readily opsonizes target cell surfaces making them 
more attractive to phagocytes and giving additional binding site to allow for 
phagocytosis.    
 9 
C3b and its breakdown products iC3b, C3dg, and C3d are important targets for 
complement receptors. Although C3b breakdown products can maintain a bond to a 
substrate they are unable to function within the C3 or C5 convertases (Jacobson and 
Weis 2008). While C3b plays a major role in continuing the complement cascade, C3a 
is creating a powerful inflammatory response through its anaphylactic activity. A recent 
review (Coulthard and Woodruff 2015) looked at the variety of roles C3a plays in the 
inflammatory response and found that it is a complex interaction which can be swayed 
by acute and chronic phase inflammation.  In an acute setting, C3a is seen as an anti-
inflammatory, preventing the mobilization of neutrophils that limits their accumulation 
within tissues, reducing the inflammatory response (Wu et al. 2013). Whereas in a 
chronic state of inflammation, C3a is deemed to be pro-inflammatory with signaling 
increasing cytokine release, increasing production of inflammatory mediators in 
monocytes/macrophages and modulating T-cell response (Lim et al. 2012; Strainic et 
al. 2013). The culmination of these findings is that C3a should be considered more of 
an “inflammatory modulator” rather than pro or anti-inflammatory.  While C3a is readily 
released, it is rapidly cleaved to C3ades-Arg, leaving it with less than 10% of its original 
biological activity (Sarma and Ward 2011). C3ades-Arg has not been seen to interact with 
the C3a Receptor, but studies have observed interactions with the C5a Receptor, 
C5aR2 (Kalant et al. 2003; Kalant et al. 2005; Chen et al. 2007), and this interaction is 
thought to contribute to the induction of triglyceride synthesis in adipocytes (Kalant et 
al. 2005).  
While C3 is considered a lynch pin within the cascade, it also plays a complex role in 
development and disease. C3 deficient mice show protection against hippocampal 
decline associated with aging (Shi et al. 2015), while mouse models of AD develop an 
increased burden of Aβ plaques (Maier et al. 2008b). The increasing complexity of C3’s 
influential function deems it important, and necessary, to fully understand the various 
associated regulators. 
1.2.3 C5 
C5 plays an important role for instigating the composition of the MAC.  Once cleaved 
by its respective convertase its two derivatives, C5a and C5b, are released (Shin et al. 
1968).  C5a is considered to be a potent anaphylatoxin with powerful chemotactic 
abilities, more so than C3a. It has been shown to increase vascular permeability, 
influence cytokine and chemokine release, along with phagocytosis (reviewed in Guo 
and Ward 2005) and has also been shown to influence macrophage polarization (Ruan 
et al. 2015).  C5b is the initiating factor for the construction the MAC, and is able to 
attract C6, C7, C8 and C9 molecules. These components come together to form a ring 
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like, porous structure (Podack et al. 1982; Tschopp et al. 1985).  This configuration is 
then able to infiltrate the plasma membrane of cells, forming a lytic pore, and supports 
the destruction of the target cell.  Although the majority of C5 activation occurs through 
the C5 convertases, there has been evidence to indicate an interaction, and activation, 
of this terminal component with the coagulation pathway (reviewed in Amara et al. 
2008). One component of this pathway demonstrated to be able to locally activate C5a 
is Thrombin (Huber-Lang et al. 2006). 
Along with being the final stage of all 3 complement pathways, C5 has been 
demonstrated to play a multitude of roles, including reassigning oligodendrocytes into a 
more precursor state (Rus et al. 1997), as well as being able to inhibit Caspase-3 
activity (Mukherjee and Pasinetti 2001). While being incorporated into the membrane 
attack complex, a low copy number of C9 can create a functional pore rather than a 
rigid lysing one (Bhakdi and Tranum-Jensen 1991).  
 
1.3 Regulating the complement cascade 
While complement is a necessary tool for tackling infection and local tissue damage, if 
left unchecked it can be detrimental to the host.  This requirement for regulation is 
provided by a group of regulatory proteins, which work by either competitively 
inhibiting, or degrading components of the C3 and C5 convertases (Fig 2, Table 1).   
Most of these regulators are located in a region defined as the Regulators of 
Complement Activation (RCA) locus, found on human Chromosome 1 at locus 1q32 
(Fig 3) (Weis et al. 1987; Rodriguez de Cordoba et al. 1985; Rodriguez de Cordoba 
and Rubinstein 1986; Lublin et al. 1987; Lublin et al. 1988; Hourcade et al. 1992). The 
RCA is highly conserved throughout many organisms, and contains the majority of the 
genes currently understood to regulate the complement cascade. Each gene within the 
RCA is generally made up a varying number of short consensus repeats (SCRs, also 
known as complement control protein (CCP) repeat sequence), 60 amino acids in 
length (Hourcade et al. 1992).  The presence of these SCRs is important as their main 
targets are the various convertases within the complement cascade. These regulatory 
proteins work in tandem to regulate the complement system, thus directing an immune 
response to invading pathogens, to clear potentially damaging debris, all while 
preventing aberrant damage to host tissue.  
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Table 1 – Regulators and Receptors of Complement 
Regulators/Receptors 
of Complement 
Alternative Names Genomic 
Location  
Target SCRs 
CR1 CD35, C3BR, C4BR 1q32 C3b, C4b, C1q, 
MBL 
30 (varies depending 
on allotype) 
CR2 CD21, C3DR 1q32 iC3b, C3d 15-16 
DAF CD55 1q32 C4b, C3b,  4 
MCP CD46 1q32 C3b, C4b 4 
CD59 N/A 11p13 C5b-9, C8, C9 N/A 
Factor H CFH, FH, HF 1q32 C3b 20 
Factor I CFI, FI, IF 4q25 C3b, C4b N/A 
C4BP C4BPA, C4BPB 1q32 C4b N/A 
Clu APOJ 8p21-p12 C5b-, C7, C8, 
C9 
N/A 
CR3 CD11b/CD18, 
ITGAM/ITGB2 
16p11.2/21q22.3 iC3b N/A 
CR4 CD11c/CD18, ITGAX 16p11.2 iC3b N/A 
C3aR1 C3AR 12p13.31 C3a, C4a N/A 
C5aR1 C5AR, C5R1, CD88 19q13.32 C5a N/A 
C1qR CD93,C1QR1, C1qRP 20p11.21 C1q N/A 
C1 Inhibitor SERPING1,C1IN, 
C1NH, C1INH 
11q12.1 C1r, C1s, 
MASP-1, MASP-
2 
N/A 
References: (Ripoche et al. 1988; Nicholson-Weller and Wang 1994; Andrews et al. 
1985; Wong et al. 1989; Klickstein et al. 1988; Iida et al. 1983; Weis et al. 1984; Moore 
et al. 1987; Fujisaku et al. 1989; Toothaker et al. 1989) 
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Figure 2. Interactions of Complement Regulators with the Cascades There are 
many regulators and receptors put in place to ensure that the complement cascade 
does not go awry.  A lot of these regulators/receptors are targeted towards the central 
component, C3, or the byproducts of its breakdown. CR1 (in bold) is integral to 
regulating C3, along with CR2 (in bold) being a receptor instigating immune cell 
response. 
 
 
Figure 3. Regulators of Complement Activation The regulators of complement 
activation (RCA) are an evolutionarily conserved family of genes.  They are found on 
Chromosome 1 at 1q32.  The genes that make up the RCA mostly contain short 
consensus repeats (SCR, also known as complement control protein repeats). Genes 
within this region tend to have C3 as a target. 
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1.3.1 CR1 
Complement Receptor 1 is a negative regulator of complement, and a known receptor 
for C3b, C4b, C1q and MBL proteins.  CR1 works as a cofactor enabling Factor I to 
cleave and hence inactivate C4b and C3b (Zhang et al. 2013). CR1 is a type 1 
transmembrane glycoprotein that is found on a multitude of immune cells and is 
considered an integral receptor for C3b and C4b (Iida et al. 1982). There are 4 known 
allotypes of CR1 in human populations, CR1-F (CR1-A) 220kDa in size, CR1-S (CR1-
B) 250kDa in size, CR1-F’ (CR1-C) 190kDa in size and CR1-D 280kDa in size 
(Dykman et al. 1983a; Dykman et al. 1983b; Dykman et al. 1984; Dykman et al. 1985; 
Van Dyne et al. 1987).   Allotypes A and B are the most common in the human 
population (Fig 4) with a prevalence of A=0.87 and B=0.11 in Caucasians, A=0.82 and 
B=0.11 in African Americans, A=0.89 and B=0.11 in Mexicans (Moulds et al. 1996), 
and A=0.916 and B=0.084 in Asian Indians (Katyal et al. 2003).  The differences 
between the 4 allotypes of CR1 is a result of the number of long homologous repeats 
(LHRs; each comprising a set of 7 SCRs) they consist of; this variation is thought to be 
due to insertion-deletion events that occurred via unequal crossing over (Holers et al. 
1987). The unequal crossing over events have led to a variation of 1.3-1.5kb between 
each allotype, with this difference being equivalent to one LHR (Holers et al. 1987; 
Wong et al. 1989). Environmental or genetic stressors are thought to have perpetuated 
these CR1 polymorphisms (Nath et al. 2005; Cockburn et al. 2004). These LHRs are 
comprised of 7 SCRs, which tend to be repetitive in nature. The SCRs have an 
inherent binding affinity which allow for localization and immobilization of various 
complement components (McLure et al. 2004). Each SCR domain is oriented such that 
it is able to interact with adjacent domains, enabling the capture of the complement 
component it is targeted to (Lehtinen et al. 2004).  Multiple SCR domains are required 
for interactions to occurs, as single SCR domains do not interact or immobilize 
potential targets (Adams et al. 1991; Coyne et al. 1992). The composition of the LHRs 
are repetitive and this is thought to facilitate the interaction of CR1 and its binding 
targets (Klickstein et al. 1987).    
The most common allotype of CR1 (CR1-A) consists of 30 SCRs, with the first 28 being 
organized into 4 LHRs. Each LHR is comprised of 7 SCRs which are homologous 
across the LHRs (Wong et al. 1989). The first three SCRs are conserved in these 
LHRs and are the domains that contain the binding site for C3b and C4b (Klickstein et 
al. 1988; Wong et al. 1989; Merle et al. 2015a).  Each LHR consists of sites able to 
bind a variety of molecules; LHR-A is able to interact with C4b and enables accelerated 
decay of C3 and C5 convertases (Klickstein et al. 1988; Krych-Goldberg et al. 1999), 
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while LHR-B and LHR-C are able to bind C3b along with C4b (Klickstein et al. 1988) 
and PfEMP1 (Rowe et al. 1997), and finally LHR-D is able to bind both C1q (Klickstein 
et al. 1997) and MBL (Krych-Goldberg and Atkinson 2001; Ghiran et al. 2000). LHR-B 
and C are also able to work together as a cofactor for Factor I, enabling the proteolytic 
cleavage of C3b and C4b into their inactivated forms; iC3b, C3c, C4c and C4d (Ross 
and Lambris 1982; Medof and Nussenzweig 1984; Sarma and Ward 2011; Merle, 
Church, et al. 2015; Krych et al. 1998; Klickstein et al. 1988; Smith et al. 2002). The 
inactive forms of C3b and C4b are now targets for other complement receptors such as 
CR2. LHR-D is a region generally associated with the various blood groups; Knops, 
McCoy, York and Swain-Langley/Villien (Moulds 1981; Moulds et al. 1991; Daniels et 
al. 1995). The variations within these blood groups are generated via a single 
nucleotide polymorphism (SNP) in exon 29 – within SCR 25 (of CR1-A) (Moulds et al. 
2004). 
 
  
Figure 4. Complement Receptor 1 (A) Complement Receptor 1 (CR1) has 4 
allotypes, with the two most common being CR1-B and CR1-A.  These genes contain a 
varying number of SCR (B) that influence the number of LHR (C) in the protein. CR1-B 
contains an extra LHR. CR1 is a membrane bound protein, containing extracellular 
LHR regions, a transmembrane (TM) region and an intracellular domain (CD) that is 
able to instigate intracellular signaling. The soluble form of CR1 (sCR1) is created via 
cleavage at the TM region by elastases and metalloproteinases. 
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Although the precise expression pattern is still being determined, reports suggest CR1 
is commonly, and in varying quantities, expressed on the plasma membrane of multiple 
blood derived cells (including erythrocytes, eosinophil, monocytes/macrophages, B-
lymphocytes, dendritic cells and a sub-set of CD4+ T-cells (Fig 5) (Weiss et al. 1989; 
Rodgaard et al. 1995; Rodgaard et al. 1991; Fang et al. 1998; Pascual et al. 1993; 
Pascual et al. 1994; Merle, Church, et al. 2015)). In the brain, CR1 may also be 
expressed on microglia, neurons (Hazrati et al. 2012) and astrocytes (Morgan and 
Gasque 1996; Fonseca et al. 2016). Erythrocyte CR1 plays an integral role in the 
clearance of soluble immune complexes and is a mediator for transporting them to 
macrophages in the spleen and Kupffer cells in the liver (Cosio et al. 1990; Craig et al. 
2002), allowing for these cells to engulf and phagocytose immune complexes (van Es 
and Daha 1984; Skogh et al. 1985). The levels of CR1 seen on erythrocytes is thought 
to differ due to a HindIII restriction fragment length polymorphism, which corresponds 
to a SNP in intron 27 of the CR1 gene (Wilson et al. 1987).  This variation is thought to 
affect the stability of mRNA, but the data for this is not clear and is deemed 
controversial. 
Several exonic SNPs have also been suggested to potentially influence the stability of 
CR1 on erythrocytes, and thus mediate the high and low levels of expression (Xiang et 
al. 1999). While this variation is seen on erythrocytes, leukocyte expression does not 
seem to show the same variability (Wilson et al. 1986). While CR1 has been 
demonstrated on CD4+ and CD8+ T lymphocytes (Rodgaard et al. 1991), the 
functional significance has yet to be elucidated, but an increased level of expression 
has been seen in activated T-cells (Rodgaard et al. 1995). CR1 is also able to 
participate in T-cell regulation/activation by inhibiting proliferation if crosslinked (Lipp et 
al. 2014). CR1, activated by iC3b, on T-cells reduces their rate of proliferation and 
secretion of IL-2 (Wagner et al. 2006). It has also been shown to contribute to the 
generation of regulatory T-cells, through the co-ligation of MCP (Török et al. 2015). The 
presence of CR1 on B-cells is considered to be a controller of proliferation (Fingeroth 
et al. 1989), as, when bound to one of its ligands, B-cells are unable to instigate 
proliferation (Józsi et al. 2002; Erdei et al. 2003).  This may be of importance for the 
prevention of auto-antigen mediated B-cell activation (Khera and Das 2009). While 
effects of CR1 have been observed on the fates of each of these cells, the precise 
mechanisms by which CR1 is acting is yet to be determined.  
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Figure 5. Complement Receptor Expressing Cells Present in the Blood The 
various cell types in the blood are derived from haematopoietic stem cells. Each cell 
comes from a particular lineage with CR1 and CR2 expression differing among these 
cell types. Blue boxes denote CR1 expressing cells, such as erythrocytes, eosinophil, 
monocytes/macrophages, B-lymphocytes, dendritic cells and T-cells. Red boxes 
denote CR2 expressing cells such as T-cell progenitors, B-cells and mature T-cells. 
 
CR1 has been shown to have phagocytic properties that have been observed on 
neutrophils and macrophages (Schorlemmer et al. 1984), with C3b thought to be 
important for this process. Once an immune complex, or LPS, is bound to CR1 a 
phagocytic response is instigated (Griffin and Mullinax 1990).  Although the presence 
of C3b is important for this process if C3b binds to CR1 without an immune complex 
attached, a phagocytic response is not induced (Griffin and Mullinax 1990).  CR1 has 
also been shown to work synergistically with Fc-gamma receptors to promote the 
uptake of opsonized immune complexes with these particles being destroyed within the 
lysosome (Ehlenberger and Nussenzweig 1977). Along with these phagocytic 
capabilities of CR1, it has also been shown to exert decay accelerating abilities, similar 
to that of DAF (Noris and Remuzzi 2013). 
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The non-membrane bound, soluble form of CR1 (sCR1) found in plasma is derived 
from membrane bound CR1 through proteolytic cleavage at the transmembrane region 
via elastases and metalloproteinases (Danielsson et al. 1994; Hamer et al. 1998; 
Sadallah et al. 1999). While plasma levels of sCR1 are considered to be too low for 
functional significance (Pascual et al. 1993), it is suggested to be locally active (Khera 
and Das 2009) as it is released locally from leukocytes, predominantly 
polymorphonuclear leukocytes (Danielsson et al. 1994). This sCR1 is observed most 
commonly during potent complement activation (Weisman et al. 1990; Mulligan et al. 
1992; Ramaglia et al. 2008). With the ability to be locally active, it enables a more 
immediate regulation of the complement cascade, allowing time for response cells to 
reach the site of activation and prevent untoward damage. CR1 is also commonly 
found in urine (uCR1), coating membrane vesicles released from the glomerular 
podocytes.  The presence of this uCR1 was demonstrated when differences in the 
allotypes of erythrocyte CR1 and uCR1 of patients who had undergone renal transplant 
were seen (Pascual et al. 1994). 
With CR1 playing a multifaceted and influential role on the regulation of the 
complement cascade, and being intertwined with the regulation of differing cell types, 
when studying the complement cascade in animal models, it is important to 
recapitulate the function of CR1 as closely as possible.  
 
1.3.2 CR2 
Complement Receptor 2 is a downstream receptor of the complement cascade, as well 
as being a bridge between the innate and adaptive immune systems. It is a 145kDa 
multi-functional glycoprotein receptor, primarily binding to the C3 fragments; iC3b, 
C3dg and C3d (Iida et al. 1983; Holers and Kulik 2007). Along with being the receptor 
for C3 fragments, it is also utilized as a receptor for the gp350/220 viral coat protein of 
the Epstein-Barr virus (EBV) (Fingeroth et al. 1984), CD23 (Aubry et al. 1992), 
Interferon-alpha (Asokan et al. 2006; Delcayre et al. 1991) and HIV-1 (Herrero et al. 
2015).  CR2 is commonly found on B-cells and follicular dendritic cells (FDC), and it 
plays an important role of bridging innate and adaptive immunity through engagement 
with the B-cell receptor (BCR). Once bound to an immune complex, CR2 will associate 
with CD19 and CD81, creating a B-cell specific signal transduction complex. This 
association results in enhanced calcium release, proliferation and activation of B-cells 
(Hannan et al. 2002).  CR2 expression has also been found on thymocytes and a sub-
population of T-lymphocytes (Fig. 5) (Levy et al. 1992; Watry et al. 1991; June et al. 
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1992). As well as this it has also been linked to intracellular signaling pathways such as 
the membrane phosphoprotein p53, nucleolin-mediated regulation of PI3-kinase (Barel 
et al. 2001; Barel et al. 2003) and antigen internalization and response (Barrault and 
Knight 2004). 
CR2 consists of 15-16 SCR arranged into 4 LHR (Fig 6), containing 3 or 4 SCR each 
(Weis et al. 1984; Moore et al. 1987; Fujisaku et al. 1989; Toothaker et al. 1989), with a 
28 amino acid transmembrane region and 34 amino acid cytoplasmic tail.  The gene is 
comprised of 16 exons, with the variance in the number of SCR being down to 
alternate splicing of a single exon (exon 11). CR2 is able to function as a receptor for 
the various degradation products of C3b, regardless of whether they are bound to 
immune complexes or free, with most of this functionality occurring within SCR-1 and 
SCR-2 (Kalli et al. 1991).   
 
Figure 6. Complement Receptor 2 (A) Complement Receptor 2 (CR2) has 2 common 
variants among human populations.  The variation occurs in the number of Short 
Consensus Repeats (SCR) present at a protein level.  This variation occurs at an 
alternate splicing level, with CR2 16 SCR containing an additional exon (exon 11). (B) 
The SCR form 4 long homologous repeats (LHR) within the protein, each having the 
capability to bind inactive and degraded fragments of C3b. 
Whilst the role of CR2 appears to be mostly as a receptor for C3b fragments, it was 
also discovered to be the receptor for EBV.  CR2 was shown to bind EBV using MHC-II 
as a co-receptor, and thus enabling the virus to take advantage of CR2 to infect B-
cells.  Along with EBV, HIV also utilizes CR2s role on FDC, a receptor for C3b bound 
immune complexes that is able to retain them for a prolonged period (Qin et al. 1998).  
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HIV also takes advantage of this retention on naïve T-cells (Moir et al. 2000), and 
enables transfer, and thus infection, of HIV incorporated complexes. This ability of HIV 
to bind to CR2 on T-cells has also been suggested to be reflected in B-cells and 
potentially FDCs (Moir and Fauci 2009).  The integral role CR2 has in the ability for HIV 
to infect has also been demonstrated through the blocking of this receptor, and 
therefore inhibiting HIV binding (Kacani et al. 2000).  
CR2 is also able to make a complex with CR1 on B-cells, which is not fully understood.  
One theory suggests the role is for both CRs to bind and stabilize iC3 (C3(H2O)) (Leslie 
et al. 2003; Nielsen et al. 2001). iC3 has a higher affinity for CR1, but is also able to 
bind to CR2. Once iC3 is bound to CR2, or the CR1/CR2 complex, it is stabilized and 
this enables the activation of the alternative pathway (Nielsen et al. 2001). The 
importance of this interaction, along with further potential roles this complex may play 
is yet to be fully determined. 
CR2 has also been shown to have the ability to save peripheral B-cells from sIgM-
mediated apoptosis (Kozono et al. 1998). The majority of research has focused on the 
role of membrane bound CR2, but more recent studies have suggested that soluble 
CR2 (sCR2) also plays various roles.  This sCR2 is potentially derived from one of two 
origins; proteolytic cleavage (Ling et al. 1998) or alternate splicing. Although it has not 
been fully elucidated as to where sCR2 is derived from, it has been noted that there is 
an increased level in the cerebrospinal fluid of multiple sclerosis patients (Lindblom et 
al. 2016). 
The signaling pathways CR2 has been shown to be integral in are with the activation 
and differentiation of B-cells (Roozendaal and Carroll 2007; Carroll 2008).  This role is 
through the co-receptor complex with CD19 and CD81 (Bohana-Kashtan et al. 2004), 
reducing the threshold for B-cell activation and enhancing intracellular calcium influx 
(Dempsey et al. 1996; Carter et al. 1991). This in turn leads to MAP kinase (MAP-K) 
activation (Tooze et al. 1997). Once CR2 is bound to an antigen complex with iC3b, it 
associates with CD19 and CD81.  Phosphorylation is initiated on CD19, which provides 
a docking site for Vav (O’Rourke et al. 1998) and PI3-K (Buhl and Cambier 1999).  This 
interaction leads to the enhanced calcium flux and MAP-K activation.  While CD19 
activates this signaling at a low level when not associated with CR2 or CD81, when 
CR2 is present this signal is amplified (Dempsey et al. 1996). The binding of iC3b 
usually instigates this signaling pathway; but lipid rafts are also able to bind the 
CR2/CD19/CD81 receptor complex and prolong the signaling activity (Cherukuri et al. 
2016; Pierce 2002).  When CR2 is in excess, it can down regulate the calcium influx 
response (Chakravarty et al. 2002). Along with initiating signaling pathways in the 
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CR2/CD19/CD81 complex, CR2 is also able to signal independently.  In addition, CR2 
is able to directly trigger the binding of pp60src to nucleolin, initiating nucleolin 
phosphorylation that activates PI3-K which, in turn, phosphorylates AKT leading to 
activation of glycogen-synthase kinase activity (Barel et al. 2003; Bouillie et al. 1999).  
Where there is much known about CR2, it is important to understand the full scope of 
its capabilities.  While cell culture studies and animal models have been essential to 
understanding a wide variety of its function, they have not been able to elucidate the 
finer details of the inner workings of the interactions between CR2 and CR1.   
 
1.4 Complement in disease  
Historically, research has focused on the role of complement components in immune 
responses, infections and autoimmune diseases. However, more recently, the role of 
the complement cascade has been expanded to include a variety of additional 
responses including the remodelling and plasticity of neuronal synapses (Stevens et al. 
2007; Schafer et al. 2012) and the dedifferentiation of cells to a more precursor-like 
state (Mastellos et al. 2013).  These different functions of complement work on a finely 
balanced scale, and if there is any aberrant regulation of these components, then 
detrimental effects can occur.  Most complement-associated diseases are related to 
defects within this regulation, potentially by modulating the levels and accessibility of 
different complement factors. The diseases associated with complement dysregulation 
include Age-Related Macular Degeneration, SLE, Rheumatoid Arthritis, AD, along with 
many others (Table 2).  
1.4.1 CR1 as a risk factor for Alzheimer’s disease (AD) 
In 2009, a genome-wide association (GWA) study identified CR1 as a potential risk 
factor for AD (Lambert et al. 2009).  This association was corroborated in 2010 
(Carrasquillo et al. 2010; Jun et al. 2010; Corneveaux et al. 2010), 2012 (Brouwers et 
al. 2012; Keenan et al. 2012; Hazrati et al. 2012) and 2013 (Van Cauwenberghe et al. 
2013).  The exact nature of the association of CR1 with AD is not well understood. One 
study (Hazrati et al. 2012) identified the risk of AD is most likely associated with the B 
allele of CR1, with CR1-A/B allotypes carrying a 1.8x higher risk of disease over the 
CR1-A/A allele in their cohort. This risk was associated with a faster rate of cognitive 
decline.  This study also identified differences in post-mortem neuronal morphology 
and distribution between the two carrier states, CR1-A/A and CR1-A/B.   Carriers of 
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CR1-A/A appeared to have a more filiform like structure to neuronal CR1, with 
expression that associated more readily with the endoplasmic reticulum, whereas the 
CR1-A/B carriers tended to have a more vesicular like pattern to CR1 expression, 
associating more highly with lysosomes inside the neurons. Along with this difference 
in gross distribution, a reduced expression level of CR1-B was seen in comparison to 
that of CR1-A. Another study (Keenan et al. 2012) identified specific CR1 SNPs 
(rs6656401 and rs4844609) that can influence the rate of cognitive decline in AD 
patients in combination with APOE status.  These SNPs are associated with the C1q 
binding region in CR1, with the patients carrying both APOE4 and rs4844609 seeing a 
faster decline in episodic memory. While the functional implications of these SNPs are 
yet to be determined, it is suggested that they may be integral in the clearance of Aβ 
through C1q binding (Hazrati et al. 2012). Young adults who carry rs6656401 were 
seen to have reduced grey matter volume in the entorhinal cortex (Bralten et al. 2011), 
an area associated with atrophy in AD patients (Braak and Braak 1991; Hyman et al. 
1984).  Biffi et al. (2010) also saw drastic differences in entorhinal cortex volume of AD 
and MCI patients depending on their CR1 genotype. Although the expression of CR1 
within these patients was seen in neurons, recently the Tenner group was unable to 
localize any CR1 expression to these cells, instead seeing a correlation with CR1 
expression with astrocytes (Fonseca et al. 2016). 
While variations in CR1 have been associated with AD through GWA and other genetic 
studies, the mechanisms by which they function is still elusive. With the expression 
patterns of CR1 varying between different studies, it is important to model these 
identified risk factor variants.  Accurately modelling CR1 will enable a more precise 
definition to its influence in diseased states, along with allowing for the determination of 
interactions that result in potential compounding phenotypes.  
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Table 2 – Various Diseases Associated with Complement Components 
Disease Complement Association References 
Alzheimer’s 
disease (AD) 
CR1 has been associated via GWA studies 
as a potential risk factor.  The implication 
of which is yet to be determined. Studies in 
mice have shown that a deficiency of C3 
leads to a higher deposition of plaques.  
Jun et al. 2010; Brouwers et al. 2012; 
Lambert et al. 2009; Keenan et al. 
2012; Hazrati et al. 2012; Carrasquillo 
et al. 2010; Van Cauwenberghe et al. 
2013; Corneveaux et al. 2010 
Systemic 
Lupus 
Erythematosus 
(SLE) 
Reduced levels of CR1 and CR2 are seen 
in patients with SLE.   Polymorphisms in 
C2 have been identified in patients 
suffering from SLE.  
Khera and Das 2009; Ross et al. 1985; 
Richardson et al. 1990; Wilson et al. 
1986; Miyakawa et al. 1981; Walport 
et al. 1985; Corvetta et al. 1991; 
Birmingham et al. 2006; Holme et al. 
1986; Moulds et al. 1996; Katyal et al. 
2003; Kumar et al. 1994; Wu et al. 
2007; Marquart et al. 1995 
Rheumatoid 
Arthritis 
CR1 has varying expression levels 
depending on cell type in RA patients.  
Studies have suggested an overall 
reduction in CR1 levels, additional work 
identified expression level are reduced 
among the B-cell and leukocyte 
populations, with neutrophils and 
monocytes seeing an increase in CR1. 
Jones et al. 1994; Kumar et al. 1994; 
Arora et al. 1998 
Malaria CR1 is important to the process of 
rosetting, particularly on erythrocytes.  
Erythrocytes deficient in CR1 were shown 
to not perform rosetting behavior when 
infected with P. falciparum, and may play 
an important role in malarial virulence. 
Khera and Das 2009; Birmingham et 
al. 2003; Xiang et al. 1999; Thomas et 
al. 2005 
CVID Mutations within the CR2 gene, whether 
homozygous or compound heterozygous, 
have been associated with CVID.  While 
commonly this disorder is associated with 
mutations in CD19, CD81 and CD21, Thiel 
et al identified a CR2 deficient male in 
2012 who had previously been 
undiagnosed with CVID. 
Thiel et al. 2012 
Schizophrenia A recent study identified polymorphisms 
within C4 as a risk factor for schizophrenia. 
Sekar et al. 2016 
Epstein Barr 
Virus (EBV) 
EBV utilizes CR2 via stabilization and 
internalization of immune complexes, to 
gain access to cells enabling it to carry out 
its life cycle. 
Fingeroth et al. 1984 
HIV HIV hijacks the stabilization and 
internalization mechanisms of CR2. C3 
and C2 both have increased expression 
levels in astrocytes of infected cultures. 
Speth et al. 1997; Moir and Fauci 
2009; Moir et al. 2000 
Age Related 
Macular 
Degeneration 
Variations within C2, C3, Factor I and C9 
have been associated with an increased 
risk. 
Seddon et al. 2013 
Multiple 
Sclerosis 
Increased levels of sCR2 observed in 
cerebrospinal fluid of patients 
Lindblom et al. 2016 
Bacterial 
Infections 
C2, C6, C7, C8, C9.  A deficiency or 
polymorphism in any of these complement 
components can leave a carrier at a 
profound risk to bacterial infections. With 
terminal components are most commonly 
susceptible to Neisseria meningitidis 
infections. 
Orren et al. 2012; Egan et al. 1994; 
Friduss et al. 1992; Ross and Densen 
1984; Joiner 1988; Nagata et al. 1989 
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1.4.2 Complement Roles in Systemic Lupus Erythematosus (SLE)  
SLE is a complex autoimmune disorder that is caused by the production of 
autoantibodies against a variety of molecules that are not specific to an organ type. 
Autoantibodies deposit on a wide array of tissues, which induces inflammation and 
causes injury to these areas (Oishi et al. 2008).  SLE is one of the most common 
diseases associated with complement dysregulation (Khera and Das 2009). CR1 levels 
are reduced in SLE patients, with a marked decline on erythrocytes (Ross et al. 1985; 
Richardson et al. 1990; Wilson et al. 1986; Miyakawa et al. 1981; Walport et al. 1985; 
Corvetta et al. 1991; Birmingham et al. 2006; Holme et al. 1986), along with leukocytes 
(Fyfe et al. 1987) and glomerular podocytes (Arora et al. 2004; Raju et al. 2001). 
Various influencing associations have been observed in CR1 and its role in SLE, which 
include; the HindIII polymorphism effecting CR1 levels on erythrocytes (Wilson et al. 
1987), proteolytic cleavage of CR1 to create a stumped peptide, along with 
transcriptional and post-translational modifications.  While the majority of these factors 
have withstood interrogation, the HindIII polymorphism has seen higher levels of 
variation in disease effects (Walport et al. 1985; Moulds et al. 1996; Katyal et al. 2003; 
Kumar et al. 1994).  Often patients with SLE are seen to have increased deposition of 
complement C3 along with its degradation products, and this is frequently described as 
an inverse correlation with the levels of CR1. 
Variations in CR2 have also been identified as a risk factor for SLE. Wu et al. (2007) 
identified a SNP within the untranslated region of CR2 that influenced the levels of 
transcriptional activity.  Additional SNPs have been found within introns and exons 
between the studied populations, which also influence the inherent level of 
susceptibility (Douglas et al. 2009). The most strongly associated SNP increased CR2 
expression, potentially promoting the development of autoimmunity and altering B-cell 
responses.  Though Wu et al identifies this SNP as influencing an upregulation of CR2 
expression, generally the levels of CR2 seen in SLE are decreased on the surface of 
B-cells (Marquart et al. 1995; Wilson et al. 1986).  
While Complement Receptors 1 and 2 are regularly identified as influential factors in 
SLE studies, it still remains unclear how they are influencing disease state. 
1.4.3 Malaria   
Malaria is caused by infection with the Plasmodium falciparum parasite, transmitted by 
the Anopheles mosquito. Merozoites invade the erythrocytes of patients and multiply 
asexually, infecting the host further and enabling the uptake of the P. falciparum by 
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mosquitos to further their life cycle as well as continuing to infect a wider population. 
The role CR1 plays in malarial infection is not clear, but it is thought that plasmodium 
PfEMP1 is able to interact with CR1 specific sites on erythrocytes, leading to rosetting. 
This rosetting occurs when PfEMP1 binds to uninfected erythrocytes and enables the 
coupling of an infected erythrocyte.  When this bond occurs, multiple erythrocyte 
rosettes are formed, which have the potential to block small capillaries.  Many CR1 
polymorphisms have been associated with malaria, with most having a connotation 
with the level of infection severity in P. falciparum malaria, such as the Q981H 
polymorphism (Birmingham et al. 2003; Xiang et al. 1999; Thomas et al. 2005).  
1.4.4 Immunodeficiency, Common Variable 7 (CVID7)   
CVID7 is an immunodeficiency disorder associated with mutations in the CR2 gene.  
Mutations that occur, whether they are compound heterozygous or homozygous, result 
in a severe reduction of CR2 expression.  Patients who present with CVID tend to have 
recurrent bacterial infections, starting from childhood, with diagnosis usually occurring 
in early adulthood. While uncommon, some patients with CVID will also present with an 
autoimmune disorder such as rheumatoid arthritis, immune thrombocytopenic purpura 
or autoimmune haemolytic anemia. One case was presented in 2012 (Thiel et al. 2012) 
of a 28-year-old male with CVID7, previously undiagnosed. Thiel et al describe the 
patient as having hypogammaglobulinemia and a severe reduction in IgD-CD27+ 
memory B-cells. Upon closer analysis, cells were devoid of CR2, internally and on the 
cell membrane, along with a lack of any sCR2 in the serum. While most other cases of 
CVID present due to mutations in CD19, CD81 or CD20, this is the first presentation of 
this disorder with a CR2 deficiency.  
 
1.5 Modelling complement in disease 
To be able to gain a more comprehensive view of the complement system mouse 
models are readily used (Howell et al. 2011; Zhou et al. 2008; Williams et al. 2013; 
Schafer and Stevens 2010; Chu et al. 2010; Stevens et al. 2007; Killick, T. R. Hughes, 
et al. 2013; Maier et al. 2008b; Stephan et al. 2013).  The ability to use an organism 
with a comparable innate immune system enables a greater insight into the emerging 
complement-independent pathways, with complement components not following the 
traditional cascade route.  Modelling this will allow for targeted therapies to be honed, 
causing minimal damage to unaffected areas. Mouse models have been an excellent 
tool for unraveling a variety of nuances surrounding complement, such as its role in 
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synaptic pruning in development (Schafer and Stevens 2010; Stevens et al. 2007), the 
importance of C3 regulators in development (Xu et al. 2000; Mao et al. 2003) and how 
a lack of certain complement factors can influence recovery from traumatic brain injury 
(Neher et al. 2014). These discoveries in mouse models have led to a much greater 
understanding of the inner workings of complement in a variety of scenarios, and have 
identified potential areas for therapeutics. 
1.5.1 Evolutionary Divergence of Human and Mouse Complement Receptors  
Elucidating the roles complement play in disease is key to designing therapeutics that 
target the cascade. Whilst our knowledge of complement is being vastly broadened 
through the use of mouse models, these models do not adequately recapitulate the 
scope of human complement receptors.  Although the three central pathways of the 
complement cascade are highly conserved between mammals, the regulators differ 
(Farries and Atkinson 1988; Nonaka 2001; Jacobson and Weis 2008). It is thought that 
during evolution, branching occurred between primates and sub-primates leading to a 
duplication/deletion event (Jacobson and Weis 2008; Holers et al. 1992).  While there 
are some similarities between the RCA of humans and mouse, a striking difference is 
that sub-primates carry no true orthologue of CR1 (Fig 7A).  The closest mouse 
equivalent of the human CR1 gene is created through alternative splicing of the mouse 
Cr2 (mCr2) gene, or Crry (Paul et al. 1989; Kurtz et al. 1990).  Given that CR2 and 
CR1 show differing expression patterns, these variations lead to differences in the 
expression pattern between human CR1 and the CR1-like mouse proteins.  These 
differences greatly limit research into understanding the mechanisms by which CR1 
and CR2 impact health and disease. 
1.5.1.1 Mouse Cr2 Produces the Closest Orthologue of Human CR1 
Mouse Cr2 (mCr2) is considered a homolog to human CR2, but unlike human CR2 
which produces one protein containing either 15 or 16 SCR, mCr2 is alternatively 
spliced to create two mouse proteins CR2 (CD21, 145KDa) and CR1 (CD35, 190kDa) 
(Fig 7). This splice site lies directly after the signal sequence in the mCr2 gene, with 
the Cd35/Cr1 (mCr1) splice variant including all 19 exons, whereas Cd21/Cr2 utilizes 
only 14. The supplementary exons in mCr1 encode for 6 additional SCRs, with binding 
domains available for C3b. Mouse Cr1 has also been demonstrated to be able to bind 
both C3b and C4b complexes while mCR2 is only able to bind the C3 fragment C3dg 
(Jacobson and Weis 2008). Both CR1 and CR2 have restricted expression patterns, 
only found in FDC and B-cells (Kaya et al. 2001; Kurtz et al. 1989; Qin et al. 1998), 
although recent reports have described expression of only the CR1 spliceform is 
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present in FDC (Donius et al. 2013). This FDC mCr2/Cr1 in mouse is not considered 
phagocytic but is an anchor for immune complexes enabling the generation of a strong 
antibody response, and aiding in the maturation of B-cells (Wu et al. 2000; Prodeus et 
al. 1998; Fang et al. 1998).   
Mouse models completely deficient in mCr2/Cr1 have shown that mCr2/Cr1 is 
implicated in the prevention of the production of auto-reactive antibodies (Prodeus et 
al. 1998; Chen et al. 2000; Wu et al. 2002). Mice with restricted deficiencies in FDC 
and B-cells show depressed T-cell antibody response to low dose immunization, along 
with a heightened sensitivity to S. pneumonia infection (Molina et al. 1996; Ahearn et 
al. 1996; Haas et al. 2002). These deficient mice also display a heightened 
inflammatory response state in their spleens, compared to their WT counterparts 
(Jacobson and Weis 2008).  Along with this, mCR2 deficient mice have been used 
extensively to study the role mCR2/CR2 plays in immune function and modulation, and 
are regularly used in research concerning autoimmune disease. 
While researchers readily use mouse CR2 as a model for human CR2, they also use 
the alternate splicing of mCR2 to model human CR1. Restriction within the expression 
of mCR2 poses difficulties in modelling CR1 due to the wider array of expression seen 
in humans. Along with this restriction in expression, mouse CR1 and CR2 both 
possess the same C-terminal, giving each the same ability to interact with CD19 and 
CD81 (Barrington et al. 2009; Kalli and Fearon 1994) (along with fragilis/Ifitm proteins 
(Smith et al. 2006)), enabling co-accessory activation of B-cell response (Matsumoto et 
al. 1991; Bradbury et al. 1992; Matsumoto et al. 1993), an activity lost in human CR1 
(Matsumoto et al. 1993). 
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Figure 7. Murine Complement Regulation (A) The Regulators of Complement 
Activation (RCA) are located in a similar region of the murine genome (Chromosome 
1).  The evolutionary divergence seen between human and mouse is with the 
presence/absence of CR1.  (B) The Cr1 isoform seen in mice is derived from alternate 
splicing from the endogenous Cr2 gene.  (C) The protein products from this alternate 
splicing have differing numbers of LHR, with an additional LHR in the Cr1 variant.  This 
additional region is able to bind C3b, whereas the Cr2 protein is only able to bind iC3b 
and C3dg.  While the binding of C3b and C4b is mostly carried out by Crry. 
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1.5.1.2 Crry is Used as an Alternative Orthologue to CR1 
Complement receptor 1-related gene/protein-y (Crry, Cr1l) is a rodent specific, 70 kDa, 
membrane bound regulator of the complement cascade.  It is considered to be a CR1 
like gene, and is able to inhibit C3b activity, while also mimicking the abilities of both 
human DAF and MCP (Li et al. 1993; Kim et al. 1995). CRRY is expressed ubiquitously 
and is highly important in the regulation of the alternative pathway (Paul et al. 1989).  
This is readily demonstrated by the perinatal lethality of Crry KO mice, with maternal 
C3 deposits seen on the placenta of Crry KO embryos giving rise to placental 
destruction by E10.5 (Xu et al. 2000; Mao et al. 2003).  This lethal phenotype is 
rescued by the complete C3 or Factor B deficiency in the mothers (Xu et al. 2000; Mao 
et al. 2003).  
CRRY has been essential in helping model human diseases, with the use of transgenic 
mouse models aiding in furthering our understanding. The role of CRRY has been 
studied in mouse models for a variety of diseases including MS (Ramaglia et al. 2012a; 
Davoust et al. 1999), AD (Killick, T. R. Hughes, et al. 2013; Maier et al. 2008a) and 
uveitis (Manickam et al. 2010). While CRRY has been a useful tool for studying gross 
complement regulation, it does not fully recapitulate CR1 in expression patterns or 
functionality, and so does not aid in the elucidation of CR1’s function. 
1.5.2 Current mouse models  
The lack of ability to truly understand the nature of murine CR1 leaves a gap in 
knowledge and hampers the elucidation of its part in disease. While CRRY has been 
an important stepping stone in our understanding of the role complement modulators 
contribute to disease (Molina et al. 2002; Davoust et al. 1999; Ramaglia et al. 2012a; 
Killick, T. R. Hughes, et al. 2013; Manickam et al. 2010; Maier et al. 2008a), its 
multifunctional role, along with differential expression patterns, muddies the waters, 
leaving us unable to tease out the finer details of how human complement receptors 
are facilitating diseased states. It is also important to be able to differentiate the 
influence CR2 and CR1 (especially the various alleles) have in disease, along with 
understanding the impact various SNPs have in disease progression or protection. As 
much as human tissues and cell lines can help us gain a crude understanding, it does 
not allow for the finer details to be determined in a complete system. 
While previous attempts have been made to further understand the roles of CR2 and 
CR1 in model systems they have not been wholly successful. Cr2 KO mice have 
helped to elucidate the importance of CR2 in humoral immune response, along with B-
 29 
cell maturation and prevention of auto-antibody production (Molina et al. 1996; Ahearn 
et al. 1996; Prodeus et al. 1998; Chen et al. 2000; Haas et al. 2002; Wu et al. 2002; 
Donius et al. 2014), but with the production of two proteins they do not reflect human 
complement regulators. 
In 2000 Marchbank et al. developed a mouse model expressing hCR2 utilizing the P1 
phage clone, containing all of the known transcriptional regulatory regions. When 
combined with a mCr2 KO background, the humoral immune function was restored and 
associations with CD19 were seen. While this is a useful model to understand the role 
of hCR2 in the B-cell and humoral immune function, especially when used in 
conjunction with a mCr2 knockout mouse, it has a reduced level of hCR2 expression. 
In 2002, Marchbank et al. developed a second mouse model carrying hCR2.  This 
model utilizes the lambda promoter, giving B-cell specific expression. These mice 
showed premature expression in B-cell development, indicating that CR2 plays an 
integral function in the development and maturation of B-cells.  Although these mice 
have been useful in identifying a potential role for CR2 in development, they showed a 
greatly diminished B-cell population, along with a reduced level of CR2 expression 
(~25% of the levels seen in humans).  While these mice have opened up avenues for 
understanding the relationship between CR2 and B-cell development and immune 
function. However, they lack sufficient expression levels making it challenging to 
understand the roles of human CR2 in health and disease. 
Along with mouse models for CR2, researchers have also worked to develop models 
for CR1. One group (Repik et al. 2005) has previously engineered a mouse model to 
carry the CR1 gene, expressed under the GATA promoter, but the expression pattern 
was restricted solely to erythrocytes.  Although this was a first step to understanding a 
more comprehensive role of immune complex transportation to the spleen and liver, it 
has not allowed for the systemic importance of this regulator to be elucidated. Along 
with this, another group created a mouse model using the F-allele of CR1, under the 
lambda promoter (Pappworth et al. 2012).  This mouse showed hCR1 expression 
restricted to B-cells, with diminished levels of expression.  While the levels of CR1 
expression were similar to those of the hCR2-int (previously reported in Marchbank et 
al. 2002s) it still does not reflect the levels seen in human populations. These mice 
were also bred to a mCR2 KO background and hCR1 was shown to not replace the 
role of CR2 in mice. When combined with hCR2 mice (under the lambda 
promoter,Marchbank et al. 2002), the presence of hCR1 was not able to rescue the 
effects of premature hCR2 expression. To date, no ‘humanized’ mouse models have 
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included the entire intergenic region between CR1 and CR2 and this may be a 
potential reason for the low expression level observed. 
Despite, their limitations, humanised CR1 and CR2 models have provided some utility. 
For instance, CR2 mouse models have played an important role in understanding the 
importance of expression timing and humoral immune response activity, but they have 
not been able to replicate expression levels seen throughout the human population.  
The ability to model this is extremely important with regards to diseases such as SLE, 
which sees a decline in CR2. The same theme resonates with the models for CR1. 
CR1 is a widely expressed protein that has not been replicated in mouse models, with 
their expression patterns being restricted to Erythrocytes or B-cells. While these mice 
have been important to the understanding of immune complex transportation, they do 
not reflect what is seen in the general populous.  Expression levels in these models are 
lower than those of a human system, so modelling diseases such as Rheumatoid 
Arthritis and SLE which see a general decline in CR1 levels.  
With this in mind, more comprehensive research models need to be made readily 
available to the research community.  This will allow the role of these complement 
regulators to be fully understood and potentially allow for more educated, targetable 
assets for human health and disease.  
 
1.6 Aim of This Study 
The aim of this thesis is to characterise a new mouse model for human CR2 and CR1 
generated by JAX Genetic Engineering Technologies. This model was created by 
targeted insertion of a construct contain both hCR2, hCR1 along with their intergenic 
region.  The construct was targeted at the endogenous mCr2, aiming to replace this 
genomic region in its entirety. With correct genomic placement within the RCA, this 
potentially enables tighter and more efficient regulation of both genes, and hopefully a 
more reflective expression pattern of hCR1 utilizing the intergenic region. 
Characterisation of this mouse model will include developing genotyping, creating an 
allelic series to mimic the more common alleles of CR1 in the population, determining 
whether the various protein products are produced and examining various cell types in 
whole blood for hCR2 and hCR1 expression.  The development and characterisation of 
this mouse will aim to further the understanding of the regulation of the complement 
cascade, and its importance in development and disease.  
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2. Materials and methods  
2.1 Mouse husbandry 
All mice were maintained on a 12/12 hour light/dark cycle.  Mice were housed in 6 inch 
duplex wean cages with pine shavings and group-housed dependent on sex at wean. 
All mice were maintained on LabDiet ® 5K67. The Institutional Animal Care and Use 
Committee (IACUC) at The Jackson Laboratory approved all mice used in this study. 
Daily monitoring of mice via routine health care checks was carried out to determine 
the general wellbeing, with any mice considered to be unhealthy being euthanized with 
IACUC approved CO2 euthanasia methods. 
2.2 Humanising Complement Receptors CR1 and CR2  
For the effective study of the role CR1 plays in health and disease JAX Genetic 
Engineering Technologies set developed a mouse model via vector targeted embryonic 
stem (ES) cells (Fig 8).  A multi-staged approach was planned to create a construct of 
such a large caliber. In silico regions were designed to encompass the human mRNA 
transcripts of Cr2 and Cr1 along with their corresponding human intergenic region 
(HIR). In parallel to this design a retrieval vector for mCr2 was utilized, targeted with a 
Spectinomycin cassette, producing a vector with the 5’ and 3’ flanking regions of mCr2. 
To ensure the integrity of the human genes, they were assembled in a linear manner.  
The human Cr2 mini gene was excised from its vector and incorporated with the HIR 
gap repair vector.  This was then targeted to the mCr2/Spectinomycin vector, with 
successful integration being determined by selection with ampicillin and kanamycin.  
The Cr1 mini gene containing vector was then targeted using Apa1 and AvrII restriction 
enzymes, excising the fragment for integration into the multigene vector. Finally, this 
multigene vector was targeted with a neomycin cassette at synthetic intron 19 in the 
human CR2 mini gene. This neomycin cassette aids in the initial identification of 
successful integration of the construct into an ES cell line.  Once the vector was 
confirmed, C57BL/6J (B6, Jax #664) ES cells were targeted with the multigene vector, 
with incorporation occurring at the genomic locus for Cr2.  ES cells were then 
transferred to a blastocyst from a B6(Cg)-Tyrc-2J/J (B6Tyr, Jax #58) and implanted into 
pseudo-pregnant females.  Litters contained a variety of chimeric pups of differing 
degrees of penetrance.  
For this model to become an asset to research communities an initial level of 
characterization must be achieved.  To ensure that this is achieved and that the model 
will be fruitful for complement research, the various alleles of CR1 will need to be 
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recreated, along with assessing if expression is present and where the expression 
might be seen within this mouse model. 
 
 
 
Figure 8. Design and Development of Humanising Complement Receptors 1 and 
2 (A) The development of the insertion vector used a multistage approach.  First the 
Cr2 region was prepared with a spectinomycin cassette, and the CR2 and HIR vector 
is prepared in parallel.  These vectors were integrated together, with the CR1 
sequence being integrated into the vector after.  Finally, a Neomycin cassette was 
insert into the synthetic intron 19 of CR2.  Once the vector was confirmed to contain 
the whole sequence in the appropriate orientation, it was incorporated into embryonic 
stem cells from C57BL/6J mice.  These were implanted into B6(Cg)-Tyrc-2J/J 
blastocysts and introduced into pseudo-pregnant females. Chimeric mice were 
produced and utilized to create an allelic series. (B) A linear depiction of the final 
construct containing the Neomycin cassette in CR2 intron 19, LoxP sites in introns 3 
and 20 of CR1, and FRT sites in introns 12 and 20 of CR1.  The LoxP and FRT sites 
enable the development of an allelic series. 
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2.3 Developing the allelic series 
Chimeric mice were received from JAX Genetic Engineering Technologies and were 
used to create the subsequent mice throughout this study. The initial stage of 
developing the allelic series was to remove the neomycin cassette embedded within 
intron 19 of CR2. This was carried out using a breeding scheme involving B6.129S4-
Gt(ROSA)26Sortm3(phiC31*)Sor/J (B6.ROSA-Phi, Jax #7743) mice. This particular strain of 
mouse targets the attB-attP region surrounding the Neomycin cassette.  Removal was 
confirmed via genotyping targeting Neomycin. Once removal was confirmed a subset 
of mice were intercrossed to establish the CR2CR1L/L allele.  Homozygous mice were 
intercrossed for a further generation to produce an experimental cohort and colony. 
The genotype for this colony represents the second most common allele in human 
populations the CR1-B.   
Heterozygous CR2CR1L/WT mice were used to create the CR2CR1S/WT and 
CR2CR1KO/WT mice.  To establish the CR2CR1Short/WT allele, CR2CR1L/WT mice were 
crossed to B6.129S4-Gt(ROSA)26Sortm1(FLP1)Dym/RainJ (B6.ROSA-Flp, Jax #9086) 
mice.  The Flp recombinase is ubiquitously expressed and targets the removal of 
exons 13-20 via the flanking FRT sites in introns 12 and 20.  The removal of these 
exons produces the shorter, more common, form of CR1 in the population – CR1-A. 
Mice that were successfully targeted, were used to establish a homozygous colony. 
These produced CR2CR1S/S mice which were then intercrossed for a further generation 
to produce a colony and cohort of mice for further characterization. 
Finally, the CR2CR1KO/WT mice were created utilizing B6.Cg-Tg(Sox2-cre)1Amc/J 
(Sox2-cre Jax #8454).  In this strain, Cre recombinase is ubiquitously expressed and 
excises the targeted region using the LoxP sites, located within introns 3 and 20, to 
create a null allele (knockout, KO).  Female B6.Sox2-cre mice were bred to male 
CR2CR1L/WT mice, as the cre is active without necessarily needing to be inherited. 
Weanlings were genotyped to ensure the removal of the targeted sequence and were 
intercrossed to establish a homozygous colony.  
2.4 Breeding schemes  
Chimeric mice from the two targeted B6 ES cell lines, 5H4 and 5E2, were bred to B6Tyr 
mice  (Fig 9).  From these, black pups were pursued for further breeding as they would 
have the construct integrated due to B6 ES cells being targeted initially.  Mice 
determined positive through genotyping for the construct were then bred to B6 mice to 
confirm germline transmission by genotyping. After germline transmission was 
confirmed, male mice from each line were sent for sperm cryopreservation, with the 
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Neomycin cassette intact. Transgenic mice from the 5H4 line were also bred to 
B6.ROSA-Phi mice to remove the neomycin cassette.  Once the cassette was removed 
mice were bred to establish the allelic series – [1] mice were intercrossed to establish 
the long allele (CR2CR1Long.B6, CR2CR1L), [2] CR2CR1L were crossed to B6.ROSA-
Flp mice to create the short allele (CR2CR1Short.B6, CR2CR1S), and [3] CR2CR1L were 
crossed to Sox2-cre mice to create the knockout allele (CR2CR1KO.B6, CR2CR1KO).  
CR2CR1S mice were then intercrossed to establish the homozygous allele for each 
strain. CR2CR1KO mice were also intercrossed to produce a homozygote colony. 
Homozygotes from the original intercrosses were then bred for a further generation to 
establish cohorts for testing. 
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Figure 9. Breeding Schemes for the Developing the Allelic Series (A) The flow 
diagram represents the generation of the allelic series through the breeding with a 
variety of site-specific recombination strains.  Each allele was eventually bred to be 
homozygous for the particular CR1 variants. Of the two-targeted ES cell lines; 5H4 was 
used to continue the development of the allelic series, whereas the 5E2 line was 
cryopreserved. (B) Mice containing the genomic construct were bred to a variety of 
strains to induce the allelic series for CR1.  The breeding of the original construct to 
B6.ROSA-Phi mice enabled the removal of the Neo cassette, leaving a “Clean” CR2 
and the CR1L allele. These mice were bred to either ROSA-FLP mice to yield the CR1S 
allele or the Sox2-cre mice to yield the CR1KO allele. 
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2.5 Genotyping 
Tail tip samples were incubated in lysis buffer (25mM NaOH, 200µM EDTA, pH12) at 
95oC for 1 hour (hr) and then neutralized (40mM Tris HCl, pH5). Primers were 
designed to identify the presence of the specific parts of the CR1/CR2 construct, along 
with primers for the endogenous Cr2 and Crry genes. These primers were designed 
using the Primer3 tool within MacVector using the genetic construct and through 
Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/).  Once primers were 
identified they were checked against species (Homo Sapiens and Mus Musculus) with 
Primer-BLAST to ensure that the identified primer pairs were unique between species 
and within the genes of interest. All primers were diluted to 20µM. All genotyping 
assays were established using a temperature gradient to determine effective annealing 
temperatures. 
The primer pairs were as follows: 
For Cr1: Forward 5’ – GTACTACGGGAGGCCATTCT – 3’ and Reverse 5’ – 
TGGCTTGGGGTACGCTC – 3’ with a product size of 708bp at an annealing 
temperature of 58.1°C.  
For the HIR Forward 5’ – TCACTCACCTCGAGCCATCT - 3’ and Reverse 5’ – 
TCAGCAGGTCTTGGCTTCAG – 3’ with a product size of 291bp at an annealing 
temperature of 59.3°C. 
For the mCr2/Cr2 insertion site: Common primer forward primer: 5’ - 
TCTTCCTCTCCTTGCTACAGG - 3’ C Cr2 Reverse: 5’ - 
AGAAGAGGTGGGGACGTTCT - 3’ and CR2 Reverse: 5’ - 
TACCAACAGCAATGGGGGTA - 3’ with the mCr2 product size at 300bp and the Cr2 
product size at 198bp with an annealing temperature of 60°C. 
For Cr1 knockout (KO): Forward 5’- TCTTGTACTACAGGGCACCG – 3’ and Reverse 
5’ – ACCTCTAGGATTAAACGGTGGGG – 3’ with a product size of 150bp if cre 
recombination has not occurred, with an annealing temp 57.5°C.  The absence of a 
band, with a CR1 positive genotype, indicated the removal of exons 4-20 and the 
knockout allele is present.  
To identify the Short (S) allele, the protocol utilized the Forward primer from the KO 
allele with the following Reverse primer 5’ – CGATCATGGCTCACTGCGAA-3’.   A 
product size of 251bp was to be expected if Flp recombination had not occurred. The 
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absence of a band, with a CR1 positive genotype, indicated Flp recombination. The 
annealing temperature for this reaction was 57.8°C.  
For Crry: Forward 5’- TTGCTAATTGGTAGTGAGGAAAGG -3’ and Reverse 5’- 
TAAGTTGTTGTGAGGCTTGGGT -3’ with a product size of 190bp and an annealing 
temperature of 55.4°C.  
All samples and primer pairs were run on the following protocol: 
1. 94°C 3minutes (min) 
2. 94°C 30seconds (sec) 
3. Annealing temp for 30sec 
4. 72°C 1min 
5. Repeat steps 2-4 39 times 
6. 72°C for 5min 
7. 10°C forever 
2.6 Establishing Cohorts 
Once homozygous mice of the various alleles were identified from the first stages of 
the intercross (CR2CR1L/L at generation N3F1, CR2CR1S/S at generation N4F1, 
CR2CR1KO/KO at generation N4F1), they were intercrossed for further generations and 
genotyped to confirm a homozygous population.  Mice were genotyped and cohorts of 
3 males and 3 females from each genotype in the allelic series were identified. A wild 
type cohort was established from a separate B6 colony, and aged alongside their 
transgenic counterparts.  At 3 months old, all mice were bled via submandibular bleed 
and tissue harvested. The exception to these cohorts was with the CR2CR1KO/KO 
colony due to reduced numbers of homozygotes being produced at N4F1.  
2.7 Timed matings and embryonic development of CR2CR1KO/KO mice 
To study the possible partial lethality in CR2CR1KO/KO mice, timed matings were 
established and embryos collected at embryonic day 7.5 (E7.5) and 12.5 (E12.5). A 
total of 5 pregnant females were harvested with a total of 23 E7.5 pups and 14 E12.5 
pups. Gross morphology was observed and posterior node and tail samples were 
taken for genotyping, respectively. 
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2.8 Isolation of specific blood-derived cells by Fluorescence Activated Cell 
Sorting (FACS) 
For all mice in all cohorts (22 mice in total), 100μl of blood was collected via 
submandibular bleeding into tubes containing 0.5M EDTA to prevent coagulation (Fig 
10).  Each sample was diluted 1:1 with 1xPhosphate Buffered Solution (1xPBS) and 
the phases separated using Ficoll via centrifugation at 400g for 30min. The serum and 
leukocyte layer were collected into fresh tubes, while 10μl of the erythrocyte and 
granulocyte fraction were collected into an additional tube.  The cells were washed with 
3x volume of 1xPBS and centrifuged at 400g for 10min and this wash was repeated 
once.  Cells were re-suspended in 3ml of FACS buffer (1% BSA in 1xPBS) and 
centrifuged at 400g for a further 6min. Cells were resuspended in 300μl of FACS buffer 
and incubated with the following antibodies for 30min on ice in the dark; leukocytes and 
serum samples - CD3e-APC (eBioscience clone: 17A2 #17-0032-82, 1:100), CD45.2-
BV421 (BioLegend clone: 104 #109832, 1:100), B220-PECy7 (BioLegend clone: RA3-
6B2 #103222, 1:100), CD41-FITC (eBioscience clone: eBioMWReg30 #11-0411-82, 
1:240), CD11b-BV605 (BioLegend clone:M1/70 #101237, 1:200); Erythrocytes and 
granulocytes – CD45.2-BV421 (1:100).   After incubation, 2ml of FACS buffer was 
added and samples were centrifuged for 6min at 400g.  The supernatant was removed 
and cells were re-suspended in 250µl of FACS buffer. Samples were filtered before 
addition of propidium iodide.  Cell sorting was carried out on the FACSAria II Sorter in 
collaboration with JAX Flow Cytometry Service.  The erythrocyte and granulocyte 
fraction was sorted into CD45.2 negative and CD45.2 positive cells respectively.  While 
the leukocyte fraction was sorted into CD3 positive (T-cells), B220 positive (B-cells), 
CD11b positive (Macrophages/Monocytes) and CD41 positive (Platelets) cells. Cells 
were sorted into RNA Later (RLT) buffer with 1% β -mercaptoethanol (β-ME) and 
stored at -80°C until RNA was extracted. Beads were used as single channel controls 
and to ensure cell viability, along with background intensities, a subsection of cells 
were used as unstained controls. For cell counts please see Appendix I. 
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Figure 10. Experimental design for Blood-Derived Cell Sorting To determine cell 
specific expression of each of the humanized genes FACS was utilized to crudely 
separate out a variety of cell types in peripheral blood.  The white blood cell and 
platelet fraction was separated using Ficoll and cells sorted into T-cells, B-cells, 
Macrophages/Monocytes and Platelets.  The red blood cell fraction was separated into 
Erythrocytes and Granulocytes. cDNA was synthesized from each division. WBC – 
White blood cell and platelet fraction, RBC - Red blood cell and Granulocyte fraction. 
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2.9 Tissue harvesting and preparation  
Mice were terminally anaesthetized using a Ketamine/Xylazine (99mg/kg Ketamine, 
9mg/kg Xylazine) mix. They were transcardially perfused with 1XPBS. Spleen was 
harvested and half was cryopreserved in the following manner: submerged in 4%PFA 
overnight, rinsed in 1xPBS, submerged in a 10% sucrose solution overnight followed 
by submerging in a 30% sucrose solution overnight. Tissue was blocked in OCT and 
stored at -80°C until sectioning. Spleen samples were sectioned at 8µm and stored at  
-80°C for further testing. The other half was snap frozen and stored at -80°C for further 
use. 
2.10 RNA and Protein preparation  
RNA and protein were extracted from the snap frozen tissue using Trizol (Thermo 
Scientific #15596026) according to manufacturer’s instructions. Briefly, samples were 
weighed and submerged into 1ml of Trizol per 0.1mg of tissue.  Each sample was 
homogenized using the OmniTipTM Homogenizer and dissociated for 5min at room 
temperature (RT).  200μl of chloroform was added per 1ml of Trizol, mixed for 15sec, 
incubated for 3min at RT and centrifuged for 15min at 12,000g.  The aqueous phase 
was removed and RNA was precipitated out of solution with isopropanol for 10min at 
RT. Samples were centrifuged at 12,000g for 15min, after which the supernatant was 
removed and pellets were washed with 75% ethanol. Samples were centrifuged for a 
final time at 7,500g for 5min. The ethanol wash was removed and the pellets were air 
dried, and re-suspended in dH2O (Sigma Aldrich #W3500).  
From the remaining non-aqueous phase, DNA was precipitated out using 100% 
ethanol and centrifuged for 12min at 12,000g.  The remaining supernatant was 
transferred into a clean tube, and protein was precipitated out of solution using 
isopropanol for 10min at RT.  Samples were centrifuged at 12,000g for 15min, and the 
remaining supernatant removed.  0.3M Guanidine HCl in 95% ethanol was used to 
wash the protein pellets, incubated for 20min with a 5min centrifugation at 7,500g.  
This was repeated a further two times.  Pellets were given a final wash in 100% 
ethanol and centrifuged at 7,500g for 5min.  A 1:1 solution containing 8M urea and 1% 
SDS was used as a resuspension buffer for the protein.  Samples were left overnight at 
+4°C before breaking down the pellet via sonication. Each sample was sonicated at 
least three times at 30sec intervals. Samples were centrifuged for 10min at 10,000g, 
the final supernatant was transferred to a new tube with protease inhibitor (Thermo 
Scientific #78440). 
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All RNA and protein samples were stored at -80°C before use. RNA Concentrations 
were determined via Nanodrop and protein concentrations via detergent compatible 
(DC) Protein Assay (Bio-Rad #5000112) respectively. 
2.11 RNA extraction for sorted cells and cDNA synthesis 
cDNA was synthesized using JAX Genome Technologies. Briefly, buffer RLT (Qiagen) 
containing 10 μl β-ME per 1 ml buffer was added to the cells. Cells were homogenized 
by vortexing. Total RNA was isolated using the RNeasy Mini kit (Qiagen) for samples 
containing >500,000 cells and the RNeasy Micro kit (Qiagen) for samples containing 
<500,000 cells, according to manufacturer’s protocols, including the optional DNase 
digest step. RNA quality was assessed using the Agilent 2100 Bioanalyzer instrument 
and RNA Pico LabChip assay (Agilent Technologies).  RNA was reverse transcribed 
with Random Decamers and M-MLV RT using the Message Sensor RT Kit (Invitrogen). 
2.12 cDNA synthesis and RT-PCR from RNA extracted from spleen 
RNA extracted via Trizol was treated with DNase at 37°C for 30min, the reaction was 
stopped on ice and 0.5M EDTA was used to deactivate the DNase. Samples were 
centrifuged and the supernatant was transferred to a new tube. A lithium 
chloride:Ethanol solution was used to precipitate the RNA overnight at -20°C. Samples 
were centrifuged at maximum speed for 20min at +4°C, the supernatant removed and 
remaining pellets were washed with 70% ethanol.  RNA was resuspended in dH2O and 
concentrations were read using the Nanodrop.  1μg of RNA was used to synthesize 
cDNA. Briefly, RNA was combined with random primers, dNTPs, RNase inhibitor, 
Multiscribe Reverse Transcriptase and made up to volume with dH2O.  The reaction 
was incubated at 25°C for 10min, 37°C for 2hr, 85°C for 5min and +4°C. Samples were 
diluted 1:4 and concentrations were read again on the Nanodrop to ensure that no 
degradation had occurred.  Samples were stored at -20°C until required.   
To assess transcription, primers were designed specifically to transcript sequence for 
mCr2, Crry, Cr1 and Cr2, with particular care taken to ensure that no repeat sequences 
were captured.  This was determined by probing the whole construct sequence with a 
variety of primers and identifying pairs that were unique to the gene of interest.  These 
primers were then run through the Primer3 program to ensure the primers were unique 
to species and gene. 100ng of cDNA was used to determine whether expression was 
present. The primers for each gene are as follows: 
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For Cr2 at exon 11: Forward: 5’- TGGGGCAGAAGGACTCCAAT -3’ and Reverse: 5’- 
GCTCCACCATGGTCGTCATA -3’ with a product size of 148bp and an annealing 
temperature of 60°C. 
For Cr1 at exon 2: Forward: 5’- TCCATTTGCCAGGCCTACCA -3’ and Reverse: 5’- 
TGCACCTGTCCTTAGCACCA -3’ with a product size of 152bp and an annealing 
temperature of 60°C. 
For Cr1 covering exon 4 and 5: Forward: 5’- TGGTTCCTCGTCTGCCACAT -3’ and 
Reverse: 5’- AGGATTGCAGCGGTAGGTCA -3’ with a product size of 178bp and an 
annealing temperature 60°C. 
For mCr2: Forward: 5’- AATGCAAGAGAACCACTAAACAGAA -3’ and Reverse: 5’- 
GCTTTTCGGTTCTTGTCACC -3’ with a product size of 250bp and an annealing 
temperature of 60°C. 
For Crry: Forward: 5’- GGAGGAGTCAAGCTAGAAGTTT -3’ and Reverse: 5’- 
GTGTTGCAGCGGTAGGTAAC -3’ with a product size of 521bp and an annealing 
temperature of 55.3°C. 
All samples were run on a 2% agarose gel at 130V for 40min and images taken using 
the GeneSnap for Syngene program. 
2.13 Western Blotting 
6% gels were hand cast to determine the size difference between the CR1L/L and 
CR1S/S alleles. Protein was diluted to 80µg of total protein with 2x Laemmli buffer 
(BioRad). Samples were denatured at 95°C for 5min and loaded onto the gel. Gels 
were run for 1hr at 150V and transferred to nitrocellulose membrane via the iBlot for 
13mins. Blots were incubated at RT for 1hr with blocking solution (5% skimmed milk 
powder block in 0.1% PBS-Tween).  Blots were then washed with 0.1% PBS-Tween for 
three 15min incubations and then incubated using rabbit-anti CD35 (Abcam 
#ab126737, 1:100) for 48hrs in 0.1% PBS-Tween on an orbital shaker at +4°C. Blots 
were washed three times in 0.1% PBS-Tween and incubated with the appropriate 
secondary (Anti-Rabbit IgG HRP 1: 50,000 Millipore #AP132P) for 1.5hrs at RT. Blots 
were then washed an additional three times and detection was carried out using ECL 
detection regents (GE Healthcare RPN2109). Blots were treated with 0.25% sodium 
azide for 2hrs at RT and washed thoroughly in 0.1% PBS-Tween. These blots were re-
blocked and re-probed with mouse anti-CD21 (Abcam #ab54253, 1:100) in 0.1% PBS-
Tween overnight at +4°C.  Blots were washed and incubated in the appropriate 
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secondary antibody (Anti-Mouse IgG HRP 1:40,000 Millipore #AP308P) for 2hrs at RT, 
washed and detected.  Finally, blots were treated with 0.25% sodium azide and probed 
with a loading control, anti-Vinculin (Abcam# ab129002, 1:10,000) in 0.1% PBS-Tween 
overnight at +4°C, washed three times, incubated with the appropriate secondary 
antibody (Anti-Rabbit HRP 1:50,000) for 1hr at RT, washed and detected. 
In addition to these antibodies, others were also tested to determine the expression of 
CR1 and CR2 in the spleen.  A variety of mouse monoclonal antibodies were tested 
(Table 3).  No signal was detected using the above method, so a variety of different 
testing paradigms were used.  They included using: TBS instead of PBS, as some 
antibodies can have their binding inhibited using PBS; primary antibody incubation 
times were adjusted in an attempt to boost binding and increase signal; a variety of 
blocking buffers along with differing concentrations of block in PBS-Tween and TBS-
Tween; and using a PVDF membrane instead of nitrocellulose, as this is deemed to be 
more sensitive. Although all these variables were tested, none of the mouse 
monoclonal antibodies showed specific binding to CR1 and CR2 (Appendix II). 
Table 3 – Complement Receptor Antibodies used herein 
Antibody Host Epitope target Western blot Immunofluorescence 
CR1 
ab126737 
Rabbit 
C-Terminus 
KGNNAHENPKEVAIHL
HSQGG SSVHPRTLQT 
NEENSRVLP 
Reactive with 
human CR1 
Minimal staining – 
possibly macrophages 
 
CR1 ab25 Mouse 
E11 clone, target 
unknown 
No detectable 
signal 
No detectable signal 
CR1 3E10 Mouse Unknown 
No detectable 
signal 
No detectable signal 
CR1 
MB135 
Mouse Unknown 
No detectable 
signal 
No detectable signal 
     
CR2 
ab54253 
Mouse Unknown  
Reactive with 
human and mouse 
CR2 
N/A 
hCR2 Mouse Unknown 
No detectable 
signal 
N/A 
1048 Mouse Unknown 
Reactive with 
human CR2 
N/A 
B Ly-4 Mouse Unknown 
Reactive with 
human CR2 
N/A 
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2.14 Immunofluorescence  
Sections of spleen were incubated with LAB solution (Polysciences #24310) for 20min, 
washed in PBT (1% TritonX-100 in 1xPBS) for 5min and incubated overnight in a 
humidified chamber at +4°C with goat anti-Iba1 (Abcam #ab5076, 1:300), rabbit anti-
CD35 (Abcam #ab126737, 1:300) and Rat anti-B220 (Biolegend, 1:300) in PBT with 
10% normal donkey serum.  Sections were washed in PBT, 3x5min, and incubated 
with their respective Alexa Fluor secondary antibody at a concentration of 1:1000 for 
2hrs in PBT: donkey anti-goat IgG 488 (Invitrogen #A11055), donkey anti-rabbit IgG 
594 (Invitrogen #A21207), and donkey anti-rat IgG 647 (Abcam #ab150155). After 
incubating with the appropriate secondary antibodies, sections were washed 3x5min in 
PBT and counterstained with DAPI (Invitrogen #D1306, 1:1000) for 5min at RT in 
1xPBS with a final wash in 1xPBS for 5min.  Slides were mounted using Aqua 
Poly/mount (PolySciences, Inc. #18606) and stored at -20°C until visualized using the 
Zeiss Axio Observer. 
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3. Results 
Previous work carried out by JAX Genetic Engineering Technologies developed a 
construct carrying both human Cr1 and human Cr2, along with the intergenic region. 
This construct was integrated into the mouse Cr2 locus of B6 ES cells, with lines 5H4 
and 5E2 demonstrating successful integration. These targeted cell lineages were 
implanted into B6Tyr blastocysts and produced 27 chimeras with >50% penetrance and 
1 chimera with <50% penetrance.  Chimeras from both lines successfully bred to B6Tyr 
mice with 30% of pups inheriting the construct. 
3.1 Protein Products are Comparable in Size to the Human Counterparts 
To estimate the predicted protein size of each protein product for CR2, CR1L/L and 
CR1S/S a combination of bioinformatics tools were utilized.  First, to determine the 
mRNA sequence from the original construct, the NCBI tool Spidey was used 
(https://www.ncbi.nlm.nih.gov/spidey/). Spidey determines the mRNA regions within a 
query sequence by comparing a cDNA sequence to a genomic sequence. Briefly, for 
each gene, the predicted gene sequence from the CR2/CR1 construct was compared 
to the human genomic sequence (retrieved from NCBI Entrez gene; CR2: 
NM_001006658, CR1:  NM_00651). Secondly, the predicted protein sequence for each 
gene was determined using Open Reading Frame finder from NCBI 
(https://www.ncbi.nlm.nih.gov/orffinder/). Finally, to determine the molecular weights of 
each predicted protein, a protein molecular weight predictor tool 
(http://www.bioinformatics.org/sms/prot_mw.html) was used. The predicted molecular 
weights are: CR2 – 148kDa, CR1L/L – 273kDa and CR1S/S – 223kDa.  
To determine the most likely isoforms created by the CR2/CR1 mouse, protein 
sequences were aligned with previously reported sequences for the various alleles of 
CR1 and CR2 using ClustalW in the MacVector program. The predicted protein 
sequence for CR2 was aligned with the isoforms containing 15 (NP_001868.2) and 16 
(NP_001006659.1) SCR sequences, and determined that the constructed sequence 
matched that of the 16 SCR variant commonly found in human populations. To align 
the CR1L/L and CR1S/S, both sequences were compared with the known sequences for 
the CR1-A (NP_000564) and CR1-B (NP_000642) alleles (Fig 11).  With the exception 
of the first few amino acids, the sequences aligned to their respective human 
counterparts precisely. This demonstrates that the CR1-A allele should be equivalently 
produced through the CR1S/S constructed sequence, and likewise the CR1-B allele 
should be produced through the CR1L/L sequence.  
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Figure 11. Alignments for Common Complement Receptor 1 Allotypes From the 
construct, each viable protein sequence was aligned to the NCBI reference sequences 
for the most common CR1 variants.  Both CR1L and CR1S align to their respective 
reference sequence.  The image is a representative of the variation between the two 
most common isoforms.  For whole sequence alignment please see Appendix (III and 
IV). 
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3.2 Chimeras Produce Viable, Construct-Carrying Pups with Successful Germline 
Transmission 
To determine the transmission of the CR2/CR1 construct, genotyping was designed to 
specific regions throughout each of the gene sets and confirmed in the first generation 
of CR2Neo/WTCR1L/WT mice (Fig 12). Targeted mice, carrying the construct were bred to 
B6 mice to ensure germline transmission, and that no part of the insert would be lost 
due to recombination.  Matings were established with male and female carriers to 
determine whether there was a sex bias to inheritance of the construct, but this was not 
seen. Both 5H4 and 5E2 lineages produced healthy pups which had successful 
transmission of the construct.  Once germline transmission was identified and the 
development of the allelic series was instigated. 
 
 
Figure 12. Confirmation of the Construct Integration and Transmission 
Genotyping was developed to determine the inheritance of each portion of the 
construct.  To ensure that the surrounding genes remained intact genotyping was 
developed to ensure Crry was not disrupted. Protocols were also developed to confirm 
the generation of the allelic series.  Genotyping for Neomycin ensured that it was 
removed from the intronic region in CR2. Samples are labeled as such: [1] 
CR2NeoCR1L/WT [2] CR2CR1L/L [3] CR2CR1S/S [4] CR2CR1KO/KO [5] WT and [6] Water, 
with [L] denoting the ladder. Neo - Neomycin 
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3.3 Possible Partial Homozygous Lethality in CR2CR1KO/KO Mice  
While establishing a cohort for CR2CR1L/L and CR2CR1S/S mice produced homozygous 
mice, with 25% of the N3F1 and N4F1 pups being determined as homozygotes, the 
CR2CR1KO/KO cohort did not follow the same pattern. Upon an initial N4F1 intercross a 
markedly reduced number of CR2CR1KO/KO were seen, with 108 pups being born, and 
only 14 were homozygotes. From these, 10 were males and 4 were female.  Therefore, 
I hypothesized that some CR2CR1KO/KO mice may fail to develop to term. To test this, 
timed mating’s were established, sperm plugs observed, and embryos harvested at 
E7.5 and E12.5.  Each uterine horn was inspected for signs of embryo resorption, or 
gaps between embryos indicating likely early resorption.  No obvious signs were seen, 
and the embryos were removed from their amnions to identify any gross morphological 
changes (Fig 13), with posterior node and tail samples taken for genotyping at their 
respective time point.  Of the 37 embryos studied at E7.5 and E12.5 only 4 were 
homozygous for CR2CR1KO/KO, with no morphological differences observed between 
CR2CR1KO/KO and CR2CR1WT/WT or CR2CR1KO/WT embryos.  Eventually, a breeding 
pair of homozygote CR2CR1KO/KO was established to produce a colony, and they 
produced homozygote pups at equivalent rates to the CR2CR1L/L and CR2CR1S/S 
colonies. This would suggest that while there is not total lethality of the CR1KO/KO 
mouse, there may be difficulties in establishing initial cohorts, due to associations that 
have been unexplored.   
The insertion and subsequent removal of large portions of genomic material has the 
potential to interrupt regular transcription of genes surrounding the area of interest. As 
the RCA is an area that is tightly regulated, with a cluster of genes in close proximity, 
there is the potential for dysregulation. Determining whether there was the potential for 
lethality within the CR2CR1KO/KO mice is important due to the lethality seen within Crry-
KO mice (Xu et al. 2000; Mao et al. 2003). Removal of the majority of the CR1 
sequence has not disturbed Crry expression, enabling development to continue. As 
expected, the loss of endogenous mCr2 has not disrupted development. 
In summary, using a combination of genomic recombineering and genotyping, these 
data show that the CR2/CR1 mouse is genetically viable.  The loss of mouse Cr2 does 
not appear to disrupt development, and no surrounding regions were disturbed. 
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Figure 13. Assessing CR1KO/KO Development (A) While the expected results were 
seen in producing a cohort for the CR1L/L and CR1S/S alleles, CR1KO/KO proved to have 
difficulties.  To investigate this, E7.5 and E12.5 were studied to determine if there were 
any developmental defects.  No gross defects, or reabsorption, were seen and only 4 
of the 37 mice showed a homozygous genotype (circled in red). (B) Tables identify the 
genotypes and sex of each embryo, M – male, F – Female, WT – Wild type, HET – 
heterozygous, HOM - homozygous. 
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3.4 Splenic Expression of CR2 and CR1 in Homozygous Mice 
To begin to assess the RNA expression of Cr2 and Cr1 we assessed spleen tissue. As 
a primary organ of complement processing the spleen is an ideal target to identify the 
expression of its receptors. cDNA was generated from 3 males and 3 females, from 
each cohort, from whole spleen to determine the successful expression of both Cr2 
and Cr1, along with ensuring that the expression of Crry was not disrupted.  Targeted 
primers confirmed that Cr2 and Cr1 were present in the spleen and that mCr2 had 
been successfully removed (Fig 14).  The presence of Crry was seen in all samples 
with no disruption observed between cohorts.  Primers designed for Cr1 targeted both 
exon 2 and a region spanning exon 4 and 5. This strategy identified that CR2CR1KO/KO 
mice produced a transcript containing only the first two exons but subsequent exons 
were excised.   
 
 
Figure 14.  RNA Expression in Spleen of Transgenic Mice To determine whether 
RNA was produced in the spleen, primers were designed to exon specific regions.  All 
mice homozygous for each allele showed expression of the human genes, but no 
expression of the mouse Cr2. WT mice showed only Cr2 and Crry expression. 
CR2CR1KO/KO mice showed RNA expression of exons 2 for CR1, but did not have any 
further RNA present, as demonstrated with the CR1 ex4/5 protocol. All samples 
showed no disruption to Crry expression. Samples are labeled as such: [L] denotes the 
ladder, [1] CR2CR1L/L Female, [2] CR2CR1L/L Male, [3] CR2CR1S/S Female, [4] 
CR2CR1S/S Male, [5] CR2CR1KO/KO Female, [6] CR2CR1KO/KO Male, [7] WT Female, [8] 
WT Male, [9] Water. 
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3.5 Western Blotting Confirmed the Presence of Human Protein in Spleen 
To confirm that the predicted CR1 and CR2 proteins corresponded to their predicted 
sizes, western blotting was used to visualize each of the protein isoforms. Wild type 
samples were used as a negative control and to determine cross reactivity of 
antibodies.  To assess the allelic variations a variety of antibodies were used, with one 
antibody showing specificity (See Material and Methods for details). Both CR2CR1L/L 
and CR2CR1S/S mice showed bands at their predicted sizes (Fig 15). The 
CR2CR1KO/KO mice showed no expression of a CR1 protein at any size. Minimal cross 
reactivity was observed within the wild type mice in the spleen. The presence of these 
bands confirms that these mice are translating the humanized genes and producing 
viable proteins.   
Testing for CR2 showed that all CR2CR1 mice showed a single band at 148kDa.  The 
wild type counterparts showed 2 bands, one at 150 kDa and another 190kDa. This is to 
be expected as the mouse Cr2 gene produces two protein products via alternate 
splicing, in contrast to the human CR2 counterpart.  These data suggest that the CR2 
insert is being correctly translated and is able to be produced in cells within the spleen.   
Therefore, the CR1L/L, CR1S/S and CR1KO/KO alleles are created through recombineering 
and produce viable protein products. With protein expression confirmed, the 
expression patterns need to be identified in the mouse model.  
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Figure 15. Protein Expression in the Allelic Series of Transgenic Mice (A) Mice 
express CR1 at the expected sizes depending on their allotype. (B) CR2CR1L/L mice 
express a larger protein than the CR2CR1S/S mice. CR2CR1KO/KO do not express any 
form of CR1. CR2 expression is comparable between the three alleles, with a single 
protein product being produced.  WT mice produce two protein products from the one 
Cr2 gene via alternate splicing. Vinculin is shown as the loading control. 
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3.6 Localising Cell Specific Presence of CR1 and CR2 
Two methods were selected to assess cell specific expression within this mouse 
model.  First, antibodies were used to determine cellular location of the CR1 protein, 
and then blood-derived cells were sorted using FACS.  RT-PCR was utilized to 
determine RNA expression in these cells. 
 
3.6.1 Immunofluorescent Co-localization within the Spleen of Transgenic Mice 
To assess the expression patterns of CR1 within the spleen of transgenic mice, 
immunofluorescence was used to determine cell specific expression. Sections were co-
stained with Iba1 and B220 in an attempt to co-localize expression within the spleen.  
Although some staining was apparent in transgenic samples the WT counterparts 
showed similar staining. Although the endogenous mCR2 had been replaced, the 
appearance of this staining made it difficult to discern whether the signal was genuine 
or whether there was cross reactivity occurring (Fig 16).  Pre-conjugated antibodies 
also showed no discernable signal preventing localization of expression to be 
effectively determined (data not shown). To be able to clearly define cell specific 
expression, and to determine antibody cross reactivity, a mCr2 knockout mouse will be 
used as a negative control in the future. 
Initial staining identified that there was auto-fluorescence present in the spleen, seen 
with the secondary controls.  In addition, non-specific binding was seen in WT samples 
with the CR1 antibody. To try to counter this, CR1 was stained with different secondary 
antibodies. This still showed non-specific staining in the WT controls.  In an attempt to 
define whether this was due to experimental method a different approach was taken.  
Two paradigms were tested with just the CR1 antibody: one with LAB solution 
incubation and one without.  Samples were incubated in either LAB solution for 20min 
or in PBT for 20min.  All slides were washed in PBT for 5min and incubated for 30min 
in PBTB (3% BSA in PBT).  CR1 antibody was diluted to 1:300 in PBTB and incubated 
at +4°C for 2 nights.  After incubation, samples were washed in PBT 3x5min and the 
appropriate secondary antibody (Alexa Fluor 594) was applied 1:1000 for 2hrs at RT in 
PBT.  Samples were washed for a further 3x5min in PBT and co-stained with DAPI.  
Slides were mounted using Aqua Polymount and visualized on the Zeiss Axio Observer 
(Fig 17).  This was repeated with the addition of Goat anti-Iba1 in an attempt to localize 
expression to specific cell types (data not shown). 
To test the mouse monoclonal antibodies in tissue, pre-conjugation was required to 
prevent any aberrant binding of secondary antibodies to the endogenous IgG’s in the 
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spleen of these mice. Although these antibodies were pre-conjugated, no specific 
staining was observed. 
 
 
 
Figure 16.  Localising Expression within the Spleen of Transgenic Mice 
Immunofluorescent staining showed cross reactivity of the antibodies in both WT and 
Homozygous CR2CR1 mice. Macrophage staining (IBA1) green, CR1 red, DAPI blue. 
Images taken at 63x. [A] Is a transgenic mouse stained for CR1, [B] shows a WT 
spleen with similar staining. [C] and [D] represent the boxed area in the respective 
images above. White arrows show similar punctate staining between the transgenic 
and control. 
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Figure 17. CR1 Staining Under Different Experimental Paradigms Differing 
blocking conditions and the use of LAB solution was used to determine whether the 
cross reactivity was based on incubation conditions with the use of just the CR1 
antibody (red) and DAPI  (blue). 
 
3.6.2 Cell Specific Expression of CR2 and CR1 in Peripheral Blood 
To determine the expression patterns of CR1, FACS was carried out on the peripheral 
blood of the allelic series and wild type mice.  Cells were sorted into T-cells, B-cells, 
Monocyte/Macrophages, Platelets, Erythrocytes and Granulocytes using various 
antibodies. RNA was extracted, DNase treated and cDNA produced (Fig 10 and 18). 
To determine the cell specific expression B-cells were first targeted (Fig 19), as the 
human CR2 is driven by the mCr2 promotor this suggests expression will be 
identifiable in this cell type. Both CR1 and CR2 were seen to be expressed in B-cells, 
with the confirmation of a lack of mCr2 throughout the allelic series.  These results also 
confirmed that the CR1KO/KO was a true null, but still expressed humanized CR2. From 
this both the CR2CR1L/L and CR2CR1S/S were screened to determine the cell specific 
expression on CR1 in each sorted cell type (Fig 20).  CR1 expression was consistently 
present in B-cells and Granulocytes (Fig 20), but multiple other cells types gave 
inconsistent expression profiles (data not shown).  Inconsistent expression was even 
observed within the erythrocyte population. This inconsistency is not entirely 
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unexpected and is thought to be due to the low levels of RNA generally found in 
mature erythrocytes.  
 
In summary, this data has shown that the CR1/CR2 construct correctly integrated into 
the mouse genome, specific allotypes of CR1 can be produced through 
recombineering, and these allotypes are expressing in multiple cell types, including B-
cells and Granulocytes.   
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Figure 18.  Cells sorted from Blood-Derived Cells Each sorted cell type, had cell 
counts taken during sorting and were averaged for each cohort (for cell numbers refer 
to Appendix I Table A and B). Bars on the graph denote the standard error of the 
mean. Representative plots of various cells sorted from the white blood cell (WBC) and 
red blood cell fractions (RBC) from age and sex matched mice for all genotypes.  [A] 
Platelets were sorted from the White blood cell (WBC) fraction and viable CD41-FITC+ 
cells were separated. [B] Monocyte/Macrophages (Mo./Ma.) were sorted from the 
WBC, CD45.2-BV421+ fraction and viable CD11b-BV605+ cells were separated. [C] T-
cells and B-cells were sorted from the WBC, CD45.2-BV421+ fraction and viable 
CD3e-APC+ (B220-PECy7-) cells were sorted separately from B220-PECy7+ (CD3e-
APC-) cells. [D] Granulocytes (Gran.) and Erythrocytes (Ery.) were sorted from the Red 
Blood Cell (RBC) fraction and separated based on their viable CD45.2-BV421 status; 
Erythrocytes were considered CD45.2-BV421- whereas Granulocytes were considered 
CD45.2-BV421+. 
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Figure 19. RNA Expression of CR1 in B-cells from Transgenic Mice Primers 
designed to specific RNA sequences were utilized to determine cell specific expression 
of CR1 in peripheral blood cells. To begin screening, B-cells were initially assessed, as 
this was the cell type that was expected to express both genes.  CR1 was expressed 
from the humanized mice and they were negative for mCr2.   The samples in each lane 
are as follows, [L] denotes Ladder [1] CR2CR1L/L Male [2] CR2CR1L/L Female [3] 
CR2CR1S/S Male [4] CR2CR1S/S Female [5] CR2CR1KO/KO Male [6] CR2CR1KO/KO 
Female [7] WT Male [8] WT Female [9] Water.  
 
 
 
 
 
 63 
                             
 
Figure 20.  Blood-Derived Cell Specific Expression in CR1L/L and CR1S/S Mice To 
assess the cell specific expression in both the CR2CR1L/L and CR2CR1S/S pooled 
samples from each cell type were tested for CR1 expression. B-cells and Granulocytes 
showed expression for CR1 in both CR2CR1L/L and CR2CR1S/S mice, showing no 
gross expression differences at initial characterization. B – B-cells, T- T-cells, M – 
Macrophages/Monocytes, E – Erythrocytes, G – Granulocytes, P - Platelets 
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4 Discussion 
4.1 Mice Successfully Inherit Humanized Genes and Express Them  
The very nature of creating a humanized mouse model is one fraught with difficulties.  
However, successful production of chimeras enabled the development of these 
humanized mice. Germline transmission was successful in both targeted cell lines, with 
no recombination or rearrangement occurring at any point throughout the construct. 
While there were initial hurdles in establishing the homozygous alleles, homozygosity 
was ultimately successful for all alleles, long, short and knockout.  This enabled the 
characterization of all the alleles for CR1, including the more prevalent ones found in 
human populations. Western blotting was able to confirm the varying protein products 
produced by the CR1 allelic series. This work also confirmed that the homozygous 
CR1 knockout did not produce a viable protein product. When it came to determining 
the cell specific expression of each allele via immunofluorescence in the spleens 
difficulties were seen.  These came from the potential cross-reactivity of antibodies with 
various other complement control proteins, as many of the complement receptor 
antibodies tend to target areas containing SCRs.  These regions are replicated 
throughout many complement regulatory proteins, and due to the expansion and 
replication of CR1 through evolution (Farries and Atkinson 1988; Jacobson and Weis 
2008), it is possible that there is non-specific binding throughout this family of genes 
across species.  To counter this inability to be certain with immunofluorescent staining, 
an RNA based approach was utilized to determine the cell specific expression in whole 
blood.  These RNA based techniques identified that there was definitive expression 
message of Cr1 and Cr2 in B-cells.  Along with this, CR1 was also seen to be 
expressed in granulocytes at an RNA level. While expression levels in other cell types 
was not immediately identified, it cannot be ruled out, this is partly due to inconsistent 
results seen in a variety of cell types.  To clarify the expression profile of these genes 
more cells will need to be sorted. RNA sequencing (a more sensitive approach than 
RT-PCR) will then be employed to determine the cell specific expression of CR1 and 
CR2. While one antibody showed specificity in western blotting, it was unclear whether 
it was specific in immunofluorescence.  The inability to define specificity within this 
setting prevented having confidence in the antibodies ability to show specificity in a 
FACS setting, so it was excluded from the cell sorting panel.  Along with this lack of 
specificity it also targeted the intracellular C-terminus, so may pose difficulties in giving 
a strong signal through FACS. Additional antibodies will also need to be identified, or 
created, to ensure specificity and protein expression, allowing for multiple techniques 
to be used to definitively define the expression patterns of CR1 and CR2. 
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4.2 Future Experiments Required for Comprehensive Validation of this Model 
Although this mouse has been identified to express the human CR2 and various alleles 
of CR1 within the spleen and peripheral blood, it is important to identify whether this 
mouse model will interact with the complement system in the mouse and function as it 
does in the human system. To do this, both CR2 and CR1 will need to be rigorously 
tested for their functional ability to bind mouse C3b, C1q and other components.  This 
will ensure that the mouse model will work in a comparative fashion to that of the 
human system. Along with determining cell specific expression in the blood and 
functional capabilities, additional work also needs to be carried out to determine cell 
specific expression within the brain.  This would be carried out via primary cell culture 
of neurons, astrocytes and microglia to determine expression at an RNA level, as there 
are currently no definitive antibodies (Fonseca et al. 2016). These experiments will aim 
to bring a consensus to an inconsistently reported field and this knowledge will then be 
able to assist in understanding the mechanistic fundamentals of CR1 and CR2 roles in 
homeostasis, development and disease in a neural environment.  
A further area that will require validation is identifying suitable antibodies that are 
readily available to the research community. While some of these antibodies worked in 
different contexts, they did not appear to work in this CR2/CR1 mouse.  Currently 
available antibodies are generally inconsistent between assays and tissues samples, 
as identified by Fonseca et al. in 2016. As this inconsistency across antibodies has 
also proved difficult in defining this mouse clearly, it is important to test future 
antibodies with the appropriate controls.  Two major controls for determining suitable 
antibodies are to use a mCr2 knockout mouse and a Crry knockout mouse.  Both of 
these mice will eliminate the potential of cross reactivity due to similarities between the 
orthologous genes. Once these varying factors have been determined, a more effective 
model will be available, that does not rely on utilizing human samples and will allow the 
understanding of CRs in a complete system. This will enable new and more consistent 
antibodies to be developed and used to illuminate previously unknown aspects of both 
CR1 and CR2 in systemic research. 
 
4.3 Implications of This Model 
The development of this mouse model will open up a gateway to further understanding 
the complement cascade.  With the discoveries made within the last decades a more 
expansive role of complement has emerged (Stevens et al. 2007; Schafer et al. 2012; 
Howell et al. 2011; Williams et al. 2016; Rutkowski et al. 2010; Mastellos and Lambris 
2002; Del Rio-Tsonis et al. 1998). It is now more important than ever to understand 
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how the complement components are regulated.  As mouse models are being used 
more readily to understand mechanisms, being able to better mimic the role of CR1 
effectively will be of great benefit. The role CR1 plays in disease has previously been 
modeled in mice using mCr2 or Crry (Prodeus et al. 1998; Chen et al. 2000; Wu et al. 
2002; Molina et al. 1996; Ahearn et al. 1996; Haas et al. 2002; Ramaglia et al. 2012b; 
Davoust et al. 1999; Killick, T. R. Hughes, et al. 2013; Maier et al. 2008b; Manickam et 
al. 2010), as they are the closest mouse orthologues to CR1.  While this has led to 
some understanding of the role CR1 can have as a regulator in disease, it does not 
fully mirror the expression and functional capabilities of CR1. It is important to 
understand its role in modulating inflammation and other roles in a disease context, 
with this new mouse model it will hopefully open up undiscovered avenues of the role 
CR2 and CR1 that were not able to be elucidated via in vitro studies.  The potential of 
this is that it could have a major impact on understanding autoimmune diseases such 
as SLE and rheumatoid arthritis, and what factors may influence this, along with the 
insights into the impact CR1 has on infectious disease, such as its influence on the 
rates of malarial infection, and understanding why CR1 is considered a risk factor for 
late onset AD and what role it may have in the progression of disease (Fig 21, Table 
4). 
 
 
Figure 21. Locations of Disease Associated SNPs within CR1 Various SNPs in 
CR1 have been associated with disease, with exon specific SNPs being targetable with 
this new mouse model. Red lines indicate an intronic SNP and blue lines indicate an 
exonic SNP.  AD – Alzheimer’s disease, E - Erythrocyte 
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Table 4 – CR1 Relevant SNPs Associated with Disease 
SNP Position  Ref Alt Disease 
Association 
Reference 
rs6701713 Chr1:207612944 Intron, 
intron 
31/39 
A G AD Naj et al. 2011 
rs6656401 Chr1:207518704 Intron, 
intron 4 
G A AD Lambert et al. 2009 
rs3818361 Chr1:207611623 Intron, 
intron 
29/37 
A G AD Hollingworth et al. 2011; 
Lambert et al. 2009 
rs4844609 Chr1:207609321 Missense, 
exon 29/37 
T A AD Keenan et al. 2012 
rs9429942 Chr1:207495285 Upstream 
variant 
C T Malaria 
Gastric 
cancer 
Teeranaipong et al. 2008; 
Zhao et al. 2015 
rs2274567 Chr1:207580276 Missense, 
exon 22/30 
A G Malaria Lan et al. 2015 
rs2296160 Chr1:207621975 Missense, 
exon 36/44 
A G Malaria Lan et al. 2015 
rs4844600 Chr1:207505962 Missense, 
exon 2 
A C,G Malaria Lan et al. 2015 
rs7525160 Chr1:207495069 Upstream 
variant 
G C Non-small cell 
lung cancer 
Yu et al. 2014 
rs6691117 Chr1:207609336 Exon 29/37 A G AD 
Erythrocyte 
sediment rate 
Ma et al. 2014; Kullo et al. 
2011 
rs17047660 Chr1:207609511 Missense, 
Exon 29/37 
A G Malaria Apinjoh et al. 2014; 
Diakite et al. 2011; Toure 
et al. 2012; Kariuki et al. 
2013 
rs12034598 Chr1:207584170 Intron, 
intron 
24/32 
A G Inflammation Naitza et al. 2012 
rs12034383 Chr1:207630250 Intron 
37/45 
G A Erythrocyte 
sediment rate 
Kullo et al. 2011 
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4.4 Long vs Short Forms of CR1 
There are a variety of human CR1 isoforms and thus it is important to understand the 
functional implications of the more common allotypes. While selection pressures, such 
as malaria, have been a major factor in some geographical regions driving the 
prevalence of certain alleles, other regions do not have these pressures. Yet there is 
still a bias towards particular allele frequencies, with CR1-A and CR1-B remaining as 
the most common allotypes but varying in relative terms between populations. The 
prevalence within these different populations are: Caucasian A=0.87 and B=0.11, 
African Americans A=0.82 and B=0.11, Mexicans A=0.89 and B=0.11 and Asian 
Indians A=0.916 and B=0.084 (Moulds et al. 1996; Katyal et al. 2003). This bias may 
be due to undiscovered molecular functions of certain CR1 isoforms that could have 
major implications in our understanding of the complement cascade.  With the 
development of this allelic series, the research community will be able to further 
decipher why there might be continued inheritance of multiple alleles of CR1. The 
research community can use these tools to gain insight into how each allele interacts 
within the complement cascade. These findings will be of importance in understanding 
and modelling human disease, and generating disease models.     
 
4.5 Investigating the Role of CR1 in Alzheimer’s disease (AD) 
With the identification of CR1 as a major risk factor for AD (Jun et al. 2010; Brouwers 
et al. 2012; Lambert et al. 2009; Keenan et al. 2012; Hazrati et al. 2012; Carrasquillo et 
al. 2010; Van Cauwenberghe et al. 2013; Corneveaux et al. 2010), a more accurate 
model needed to be developed to understand how variation in CR1 increases 
susceptibility to this disease. While a variety of SNPs have been identified to link CR1 
with AD (Corneveaux et al. 2010; Carrasquillo et al. 2010; Jun et al. 2010; Brouwers et 
al. 2012; Lambert et al. 2009; Keenan et al. 2012; Van Cauwenberghe et al. 2013), one 
study suggested that carrying both the CR1-A and CR1-B alleles represents a major 
risk factor (Hazrati et al. 2012). As these various alleles do not exist in any orthologue 
in mouse models of AD, it has not been possible to determine the importance of 
allotype in disease progression and prevalence. The influence of this heterozygous 
allotype could now be understood with this model.  In addition, in 2012, Keenan et al 
identified a novel SNP within the C1q/MBL binding domain of CR1 in patients with AD.  
This SNP resulted in an increase in the decline of episodic memory. Further, co-
inheritance with the ε4 allele of APOE compounded the effect of memory decline. The 
availability of the humanized CR2/CR1 mouse model will enable for the first time the 
functional consequences of the CR1 coding variants to be assessed. At JAX, we are 
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currently using gene editing by CRISPR to introduce the coding variant identified by 
Keenan and colleagues (Keenan et al. 2012) into our CR2/CR1 mouse.  Additional 
work has seen the risk factor rs6656401 for AD also being correlated with reduced grey 
matter in the entorhinal cortex of young adults (Bralten et al. 2011), which suggests 
that CR1 may play a role in modelling the developing brain. While general associations 
of CR1 with AD are thought to be through the clearance pathways of Aβ (Hazrati et al. 
2012), no true mechanism has been elucidated.  With the availability of the allelic 
series within this mouse, and utilizing new gene editing technologies, it can be readily 
used to identify the strength and involvement of these risk factors on disease state. 
To assess the role of CR1 in AD, we now plan to breed the various alleles into a 
mouse strain already carrying AD relevant mutations.  These mutations are known 
early onset AD genes, such as APP (Goate et al. 1991; Murrell et al. 1991; Chartier-
Harlin et al. 1991) and PSEN1 (Schellenberg et al. 1992).  APP is a membrane bound 
protein that is cleaved via a variety of secretases (De Strooper and Annaert 2000).  
Mutations within these genes can affect the secretase cleavage sites, causing an 
imbalance in the level of Aβ40/Aβ42 produced.  The imbalance favours the creation of 
Aβ42, a “stickier” protein than Aβ40, which is the main component of senile plaques, a 
hallmark feature of AD (Selkoe 1994).  PSEN1 is a gamma secretase, which is able to 
cleave APP into these Aβ components.  Mutations within this gene alter its ability to 
cleave APP in the correct ratio, leading to higher levels of Aβ42 being produced (Duff 
et al. 1996; De Strooper et al. 1998). One of the more common strains of mice that 
utilize mutations in these particular genes is the APP/PS1 strain (B6.Cg-
Tg(APPswe,PSEN1dE9)85Dbo/Mmjax Jax#5864, MMRC# 34832-JAX (Jankowsky et 
al. 2004)).  Utilizing this APP/PS1 strain, a model could be developed to understand 
the role of the various CR1 alleles in AD, along with being able to test the different 
GWAS identified SNPs. 
While studying this model on an AD susceptible background will enable a deeper 
understanding of the influence CR1 has in disease status and progression, it is also 
important to be able to elucidate the genetic interaction APOEε4 and CR1 have.  While 
both have been identified separately as major risk factors for AD, they have more 
recently been identified to have a compounding detrimental phenotype in late onset AD 
cases, specifically with the rs4844609 SNP (Keenan et al. 2012).  Little has been 
uncovered about this potent effect, as it is difficult to fully dissect how each gene 
influences the other in human genetic studies.  The use of this mouse model, in 
combination with a humanized APOEε4 model, while using CRISPR to introduce the 
disease associated SNPs, will enable the research community to fully elucidate the 
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molecular mechanisms that underpin how these two disease alleles work in concert to 
create a significantly higher risk factor for AD behavioural deterioration.  
 
4.6 Conclusion 
The work described in this thesis and the models created have the potential to 
profoundly impact the complement research community.  The ability to adequately 
model CR1 and CR2 in a model system, such as the mouse, will give a greater 
understanding into why the complement cascade has been so heavily conserved 
throughout evolution along with its role in development and disease. A more complete 
understanding of the complement cascade, and its regulators, will lead to more 
targeted and personalized therapeutics.  
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6. Appendix 
Appendix I 
Table A – Cell counts per sample and cell type 
Cohort Sex CD3 B220 CD41 CD11b CD45 + 
CD45- 
WT F 16542 14808 217331 4083 1265 
1*10^6 
WT F 45550 48423 689808 18780 289 
1*10^6 
WT F 32069 33179 619628 9226 127 
1*10^6 
WT M 8581 7548 372348 12619 602 
1*10^6 
WT M 27942 29408 449116 9588 127 
1*10^6 
WT M 5744 5375 151916 5838 354 
1*10^6 
CR2CR1L/L F 51000 78000 185000 10000 1434 
1*10^6 
CR2CR1L/L F 15751 24694 146000 4922 1777 
1*10^6 
CR2CR1L/L F 21348 23379 371947 7282 572 
1*10^6 
CR2CR1L/L M 45172 54383 295458 6940 481 
1*10^6 
CR2CR1L/L M 25349 32538 207249 6999 798 
1*10^6 
CR2CR1L/L M 45285 48806 512879 13238 503 
1*10^6 
CR2CR1S/S F 31297 25273 587000 2702 151 
1*10^6 
CR2CR1S/S F 16333 20259 157345 1123 244 
1*10^6 
CR2CR1S/S F 11031 8778 109886 5015 1210 
1*10^6 
CR2CR1S/S M 14538 17479 319093 4792 219 
1*10^6 
CR2CR1S/S M 9529 12652 77010 2891 411 
1*10^6 
CR2CR1S/S M 1358 1909 457812 1183 1002 
1*10^6 
CR2CR1KO/KO F 27914 30758 400669 16725 1019 
1*10^6 
CR2CR1KO/KO F 28374 32558 370961 10325 704 
1*10^6 
CR2CR1KO/KO M 42090 59187 378278 11725 1272 
1*10^6 
CR2CR1KO/KO M 40636 40333 1000000 44910 1077 
1*10^6 
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Appendix I 
Table B – Average Cell counts per cohort per cell type 
Cohort Sex CD3 B220 CD41 CD11b CD45 + CD45 -  
WT F 31387 32137 508922 10696 560 1*10^6 
WT M 14089 14110 324460 9348 361 1*10^6 
CR2CR1L/L F 29366 42024 234316 7401 1261 1*10^6 
CR2CR1L/L M 38602 45242 338529 9059 594 1*10^6 
CR2CR1S/S F 19554 18103 284744 2947 535 1*10^6 
CR2CR1S/S M 8475 10680 284638 2955 544 1*10^6 
CR2CR1KO/KO F 28144 31658 385815 13525 862 1*10^6 
CR2CR1KO/KO M 41363 49760 689139 28318 1175 1*10^6 
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Appendix II 
Testing human complement receptor expression by Western blotting using 
various commercially available antibodies and antibodies provided by Prof. Paul 
Morgan. The antibodies tested produced a variety of results.  Overall, 
antibodies gave inconclusive results. Some (e.g. B and C) showed no obvious 
specific binding, whereas the other antibodies (A, D and E) demonstrated 
expression of the hCR1 and hCR2 proteins - but with suspected non-specific 
staining also. Further work is required to validate CR1 and CR2 protein 
expression in the mouse, potentially using mouse Cr2 KO animals, additional 
antibodies and western blotting conditions.
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Appendix III 
Full sequence alignment of the CR1 proteins 
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Appendix IV 
Full sequence alignment of the human CR2 sequences
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Appendix V 
Suppliers for consumables used throughout this thesis 
Abcam 
1 Kendall Square, Suite B2304  
Cambridge, MA USA 02139 
 
Agilent Technologies 
5301 Stevens Creek Blvd 
Santa Clara, CA USA 95051 
 
BioLegend 
9727 Pacific Heights Blvd 
San Diego, CA USA 92121 
 
Bio-Rad Technologies 
Life Science Research, Education, Process Separations, Food Science 
2000 Alfred Nobel Drive 
Hercules, California USA 94547 
 
eBioscience, Inc. 
Headquarters 
10255 Science Center Drive 
San Diego, CA USA 92121 
 
EMD Millipore 
290 Concord Road 
Billerica 
Massachusetts 01821 
United States of America 
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GE Healthcare Bio-Sciences  
P.O. Box 643065 Pittsburgh,  
PA 15264-3065 
United States of America 
 
Integrated DNA Technologies, Inc. 
1710 Commercial Park  
Coralville, Iowa USA 52241  
 
Invitrogen 
168 Third Avenue 
Waltham, MA USA 02451 
 
The Jackson Laboratory (JAX, JAX Genomic Engineering Technologies, JAX Flow 
Cytometry Service, JAX Genome Technologies) 
600 Main Street 
Bar Harbor, ME USA 04609 
 
LabDiet  
PO Box 19798  
St. Louis, MO USA 63144 
 
Polysciences, Inc. 
400 Valley Road 
Warrington, PA  USA18976 
 
Qiagen Inc. 
27220 Turnberry Lane Suite 200  
Valencia, CA USA 91355 
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Sigma-Aldrich 
3050 Spruce St. 
St. Louis, MO USA 63103 
 
Thermo Fisher Scientific 
168 Third Avenue 
Waltham, MA USA 02451 
 
Zeiss Microscopy 
One Zeiss Drive 
Thornwood, NY 10594 
USA 
